You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameLevofloxacin
Accession NumberDB01137  (APRD00477, DB06085)
TypeSmall Molecule
GroupsApproved, Investigational
DescriptionA synthetic fluoroquinolone (fluoroquinolones) antibacterial agent that inhibits the supercoiling activity of bacterial DNA gyrase, halting DNA replication. [PubChem]
Structure
Thumb
Synonyms
(-)-Ofloxacin
(3S)-(-)-9-Fluoro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-2,3-dihydro-7H-pyrido[1,2,3-de][1,4]benzoxazine-6-carboxylic acid
(S)-(-)-9-Fluoro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-2,3-dihydro-7H-pyrido[1,2,3-de][1,4]benzooxazine-6-carboxylic acid
(S)-9-Fluoro-2,3-dihydro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-7H-pyrido(1,2,3-de)-1,4-benzoxazine-6-carboxylic acid
(S)-Ofloxacin
L-ofloxacin
Levofloxacine
Levofloxacino
Levofloxacinum
Ofloxacin S-(-)-form
External Identifiers
  • MP-376
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Act LevofloxacinTablet500 mgOralActavis Pharma Company2009-06-24Not applicableCanada
Act LevofloxacinTablet750 mgOralActavis Pharma Company2009-06-24Not applicableCanada
Act LevofloxacinTablet250 mgOralActavis Pharma Company2009-06-24Not applicableCanada
Auro-levofloxacinTablet500 mgOralAuro Pharma Inc2016-04-12Not applicableCanada
Auro-levofloxacinTablet750 mgOralAuro Pharma Inc2016-04-12Not applicableCanada
Auro-levofloxacinTablet250 mgOralAuro Pharma Inc2016-04-12Not applicableCanada
Ava-levofloxacinTablet250 mgOralAvanstra Inc2011-09-152014-08-21Canada
Ava-levofloxacinTablet500 mgOralAvanstra Inc2011-09-152014-08-21Canada
Dom-levofloxacinTablet250 mgOralDominion PharmacalNot applicableNot applicableCanada
Dom-levofloxacinTablet500 mgOralDominion PharmacalNot applicableNot applicableCanada
Dom-levofloxacinTablet750 mgOralDominion PharmacalNot applicableNot applicableCanada
IquixSolution15 mg/mLOphthalmicVistakon Pharmaceuticals LLC2004-06-01Not applicableUs
LevaquinTablet, film coated250 mg/1OralPhysicians Total Care, Inc.2000-05-12Not applicableUs
LevaquinTablet, film coated750 mg/1OralJanssen Pharmaceuticals, Inc.1996-12-20Not applicableUs
LevaquinTablet, film coated500 mg/1OralRed Pharm Drug Inc.1996-12-20Not applicableUs
LevaquinTablet, film coated500 mg/1OralRebel Distributors Corp1996-12-20Not applicableUs
LevaquinSolution25 mg/mLOralPatriot Pharmaceuticals, Inc.2013-07-012016-12-07Us
LevaquinTablet, film coated250 mg/1OralCardinal Health1996-12-20Not applicableUs
LevaquinTablet250 mgOralJanssen Inc1997-11-282014-10-27Canada
LevaquinTablet, film coated250 mg/1OralREMEDYREPACK INC.2013-04-112016-10-13Us
LevaquinSolution25 mg/mLOralJanssen Pharmaceuticals, Inc.2004-10-21Not applicableUs
LevaquinTablet, film coated750 mg/1OralPhysicians Total Care, Inc.2005-08-02Not applicableUs
LevaquinTablet, film coated750 mg/1OralREMEDYREPACK INC.2016-05-26Not applicableUs
LevaquinTablet, film coated750 mg/1OralRed Pharm Drug Inc.1996-12-20Not applicableUs
LevaquinTablet, film coated750 mg/1OralRebel Distributors Corp1996-12-20Not applicableUs
LevaquinInjection, solution5 mg/mLIntravenousJanssen Pharmaceuticals, Inc.1996-12-20Not applicableUs
LevaquinTablet, film coated750 mg/1OralPd Rx Pharmaceuticals, Inc.1996-12-20Not applicableUs
LevaquinTablet, film coated500 mg/1OralLake Erie Medical DBA Quality Care Products LLC2011-01-27Not applicableUs
LevaquinTablet, film coated250 mg/1OralJanssen Pharmaceuticals, Inc.1996-12-20Not applicableUs
LevaquinTablet, film coated500 mg/1OralCardinal Health1996-12-20Not applicableUs
LevaquinTablet, film coated250 mg/1OralRed Pharm Drug Inc.1996-12-20Not applicableUs
LevaquinTablet, film coated500 mg/1OralPd Rx Pharmaceuticals, Inc.1996-12-20Not applicableUs
LevaquinInjection, solution5 mg/mLIntravenousJanssen Pharmaceuticals, Inc.1996-12-20Not applicableUs
LevaquinTablet, film coated500 mg/1OralA S Medication Solutions1996-12-20Not applicableUs
LevaquinTablet, film coated500 mg/1OralPd Rx Pharmaceuticals, Inc.1996-12-20Not applicableUs
LevaquinTablet, film coated500 mg/1OralPhysicians Total Care, Inc.2000-05-11Not applicableUs
LevaquinTablet, film coated500 mg/1OralJanssen Pharmaceuticals, Inc.1996-12-20Not applicableUs
LevaquinTablet, film coated750 mg/1OralCardinal Health1996-12-20Not applicableUs
LevaquinTablet, film coated500 mg/1OralREMEDYREPACK INC.2013-04-102016-10-13Us
LevaquinInjection, solution5 mg/mLIntravenousJanssen Pharmaceuticals, Inc.1996-12-20Not applicableUs
LevaquinTablet, film coated500 mg/1Oralbryant ranch prepack1996-12-20Not applicableUs
Levaquin 25mg/mlSolution25 mgIntravenousJanssen Inc1998-01-292006-08-04Canada
Levaquin 500mgTablet500 mgOralJanssen Inc1997-11-282015-04-02Canada
Levaquin 5mg/mlSolution5 mgIntravenousJanssen Inc1997-11-282014-03-19Canada
Levaquin 750mgTablet750 mgOralJanssen Inc2004-01-302015-03-27Canada
LevofloxacinTablet250 mgOralCobalt Pharmaceuticals CompanyNot applicableNot applicableCanada
LevofloxacinTablet500 mgOralPro Doc Limitee2013-11-28Not applicableCanada
LevofloxacinTablet500 mgOralCobalt Pharmaceuticals CompanyNot applicableNot applicableCanada
LevofloxacinTablet750 mgOralCobalt Pharmaceuticals CompanyNot applicableNot applicableCanada
Levofloxacin In 5% Dextrose InjectionSolution5 mgIntravenousHospira Healthcare Corporation2011-12-23Not applicableCanada
Levofloxacin InjectionSolution5 mgIntravenousTeva Canada LimitedNot applicableNot applicableCanada
Mylan-levofloxacinTablet250 mgOralMylan Pharmaceuticals Ulc2009-06-24Not applicableCanada
Mylan-levofloxacinTablet500 mgOralMylan Pharmaceuticals Ulc2009-06-24Not applicableCanada
Ntp-levofloxacinTablet250 mgOralTeva Canada LimitedNot applicableNot applicableCanada
Ntp-levofloxacinTablet500 mgOralTeva Canada LimitedNot applicableNot applicableCanada
Ntp-levofloxacinTablet750 mgOralTeva Canada LimitedNot applicableNot applicableCanada
PHL-levofloxacinTablet750 mgOralPharmel IncNot applicableNot applicableCanada
PHL-levofloxacinTablet250 mgOralPharmel IncNot applicableNot applicableCanada
PHL-levofloxacinTablet500 mgOralPharmel IncNot applicableNot applicableCanada
PMS-levofloxacinTablet250 mgOralPharmascience Inc2009-06-24Not applicableCanada
PMS-levofloxacinTablet500 mgOralPharmascience Inc2009-06-24Not applicableCanada
PMS-levofloxacinTablet750 mgOralPharmascience Inc2009-06-24Not applicableCanada
QuinsairSolution240 mgRespiratory (inhalation)Raptor Pharmaceuticals IncNot applicableNot applicableCanada
QuixinSolution5 mg/mLOphthalmicVistakon Pharmaceuticals LLC2000-10-01Not applicableUs
Sandoz LevofloxacinTablet250 mgOralSandoz Canada Incorporated2009-06-24Not applicableCanada
Sandoz LevofloxacinTablet500 mgOralSandoz Canada Incorporated2009-06-24Not applicableCanada
Sandoz LevofloxacinTablet750 mgOralSandoz Canada Incorporated2009-06-24Not applicableCanada
Teva-levofloxacinTablet250 mgOralTeva Canada Limited2004-11-30Not applicableCanada
Teva-levofloxacinTablet500 mgOralTeva Canada Limited2004-11-30Not applicableCanada
Teva-levofloxacinTablet750 mgOralTeva Canada Limited2009-06-24Not applicableCanada
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Apo-levofloxacinTablet500 mgOralApotex Inc2009-06-24Not applicableCanada
Apo-levofloxacinTablet750 mgOralApotex Inc2009-06-24Not applicableCanada
Apo-levofloxacinTablet250 mgOralApotex Inc2009-06-24Not applicableCanada
LevaquinTablet250 mg/1OralDIRECT RX2016-05-26Not applicableUs
LevofloxacinTablet, film coated500 mg/1OralApotheca Inc.2012-03-22Not applicableUs
LevofloxacinTablet, film coated500 mg/1OralMedsource Pharmaceuticals2011-06-20Not applicableUs
LevofloxacinTablet, film coated750 mg/1OralLake Erie Medical DBA Quality Care Products LLC2011-06-21Not applicableUs
LevofloxacinTablet, film coated750 mg/1OralSandoz Inc2011-06-20Not applicableUs
LevofloxacinInjection, solution5 mg/mLIntravenousSandoz Inc2011-07-07Not applicableUs
LevofloxacinInjection, solution, concentrate500 mg/20mLIntravenousAuro Medics Pharma Llc2013-01-24Not applicableUs
LevofloxacinTablet750 mg/1OralWockhardt Limited2011-06-20Not applicableUs
LevofloxacinTablet, film coated750 mg/1OralZydus Pharmaceuticals (USA) Inc.2012-11-10Not applicableUs
LevofloxacinTablet750 mg/1OralProficient Rx LP2012-03-30Not applicableUs
LevofloxacinTablet, film coated750 mg/1OralRed Pharm Drug, Inc.2011-06-20Not applicableUs
LevofloxacinTablet, film coated750 mg/1OralProficient Rx2011-06-20Not applicableUs
LevofloxacinTablet, film coated250 mg/1OralCadila Healthcare Limited2012-11-10Not applicableUs
LevofloxacinTablet, film coated750 mg/1OralMajor Pharmaceuticals2013-12-01Not applicableUs
LevofloxacinTablet, film coated750 mg/1OralPd Rx Pharmaceuticals, Inc.2011-06-20Not applicableUs
LevofloxacinTablet, film coated750 mg/1OralPreferred Pharmaceuticals, Inc.2015-01-08Not applicableUs
LevofloxacinTablet, film coated500 mg/1OralRebel Distributors Corp2011-06-20Not applicableUs
LevofloxacinInjection, solution5 mg/mLIntravenousWG Critical Care, LLC2016-04-14Not applicableUs
LevofloxacinTablet, film coated250 mg/1OralTeva Pharmaceuticals USA Inc2011-06-202016-05-31Us
LevofloxacinTablet, film coated750 mg/1OralMacleods Pharmaceuticals Limited2012-03-22Not applicableUs
LevofloxacinTablet, film coated500 mg/1OralPhysicians Total Care, Inc.2011-06-22Not applicableUs
LevofloxacinTablet, film coated500 mg/1OralAurobindo Pharma Limited2011-06-20Not applicableUs
LevofloxacinTablet, film coated500 mg/1OralLucid Pharma Llc2011-06-20Not applicableUs
LevofloxacinTablet, film coated250 mg/1OralDIRECT RX2014-01-01Not applicableUs
LevofloxacinTablet, film coated250 mg/1OralJubilant Cadista Pharmaceuticals Inc.2012-12-02Not applicableUs
LevofloxacinTablet, film coated500 mg/1OralReady Meds2011-06-20Not applicableUs
LevofloxacinTablet, film coated750 mg/1OralA S Medication Solutions2011-06-20Not applicableUs
LevofloxacinInjection5 mg/mLIntravenousFresenius Kabi USA, LLC2013-06-20Not applicableUs
LevofloxacinTablet, film coated500 mg/1OralAmerican Health Packaging2011-07-01Not applicableUs
LevofloxacinSolution / drops5 mg/mLTopicalPACK Pharmaceuticals, LLC2010-12-20Not applicableUs
LevofloxacinTablet, film coated250 mg/1OralNorthwind Pharmaceuticals2015-05-14Not applicableUs
LevofloxacinSolution25 mg/mLOralDepartment Of State Health Services, Pharmacy Branch2011-06-21Not applicableUs
LevofloxacinTablet, film coated250 mg/1OralAv Kare, Inc.2013-07-122016-10-13Us
LevofloxacinTablet, film coated500 mg/1OralCamber Pharmaceuticals, Inc.2015-01-09Not applicableUs
LevofloxacinTablet500 mg/1OralMajor Pharmaceuticals2011-06-23Not applicableUs
LevofloxacinTablet, film coated250 mg/1OralCardinal Health2013-12-01Not applicableUs
LevofloxacinTablet500 mg/1OralNew Horizon Rx Group, LLC2013-08-25Not applicableUs
LevofloxacinTablet, film coated500 mg/1OralA S Medication Solutions2011-06-20Not applicableUs
LevofloxacinTablet, film coated750 mg/1OralLupin Pharmaceuticals, Inc.2011-06-20Not applicableUs
LevofloxacinTablet, film coated250 mg/1OralA S Medication Solutions2011-06-20Not applicableUs
LevofloxacinTablet, film coated500 mg/1OralAidarex Pharmaceuticals LLC2012-03-22Not applicableUs
LevofloxacinTablet, film coated750 mg/1OralDIRECT RX2015-01-01Not applicableUs
LevofloxacinTablet250 mg/1OralWockhardt USA LLC.2011-06-20Not applicableUs
LevofloxacinTablet, film coated500 mg/1OralBlenheim Pharmacal, Inc.2013-11-13Not applicableUs
LevofloxacinTablet, film coated500 mg/1OralPd Rx Pharmaceuticals, Inc.2011-06-20Not applicableUs
LevofloxacinTablet750 mg/1OralPreferred Pharmaceuticals, Inc.2013-02-04Not applicableUs
LevofloxacinTablet500 mg/1OralAidarex Pharmaceuticals LLC2011-06-20Not applicableUs
LevofloxacinInjection, solution250 mg/50mLIntravenousWest Ward Pharmaceuticals Corp2011-09-16Not applicableUs
LevofloxacinTablet500 mg/1OralWest ward Pharmaceutical Corp2011-06-21Not applicableUs
LevofloxacinInjection, solution5 mg/mLIntravenousClaris Lifesciences Inc.2013-07-01Not applicableUs
LevofloxacinTablet250 mg/1OralCardinal Health2011-06-23Not applicableUs
LevofloxacinTablet250 mg/1OralTorrent Pharmaceuticals Limited2011-06-20Not applicableUs
LevofloxacinSolution / drops5 mg/mLOphthalmicHi Tech Pharmacal Co., Inc.2011-02-10Not applicableUs
LevofloxacinTablet, film coated500 mg/1OralLake Erie Medical DBA Quality Care Products LLC2011-06-20Not applicableUs
LevofloxacinSolution5 mg/mLOphthalmicAkorn Inc.2011-03-01Not applicableUs
LevofloxacinInjection, solution5 mg/mLIntravenousSandoz Inc2011-07-07Not applicableUs
LevofloxacinInjection, solution, concentrate750 mg/30mLIntravenousAuro Medics Pharma Llc2013-01-24Not applicableUs
LevofloxacinTablet, film coated250 mg/1OralCitron Pharma LLC2011-06-20Not applicableUs
LevofloxacinInjection, solution250 mg/50mLIntravenousAuro Medics Pharma Llc2016-02-10Not applicableUs
LevofloxacinTablet250 mg/1OralCipla USA Inc.2012-03-30Not applicableUs
LevofloxacinInjection, solution5 mg/mLIntravenousSagent Pharmaceuticals2011-12-05Not applicableUs
LevofloxacinTablet, film coated500 mg/1OralProficient Rx LP2011-06-20Not applicableUs
LevofloxacinTablet, film coated500 mg/1OralCadila Healthcare Limited2012-11-10Not applicableUs
LevofloxacinTablet, film coated250 mg/1OralBoca Pharmacal, LLC2012-08-17Not applicableUs
LevofloxacinTablet, film coated500 mg/1OralBlenheim Pharmacal, Inc.2013-09-05Not applicableUs
LevofloxacinTablet, film coated250 mg/1OralPd Rx Pharmaceuticals, Inc.2011-06-20Not applicableUs
LevofloxacinTablet, film coated750 mg/1OralPreferred Pharmaceuticals, Inc.2013-11-14Not applicableUs
LevofloxacinTablet, film coated750 mg/1OralRebel Distributors Corp2011-06-20Not applicableUs
LevofloxacinTablet, film coated750 mg/1OralREMEDYREPACK INC.2016-04-142016-10-26Us
LevofloxacinTablet, film coated500 mg/1OralTeva Pharmaceuticals USA Inc2011-06-202016-06-30Us
LevofloxacinInjection, solution25 mg/mLIntravenousClaris Lifesciences Inc.2013-07-01Not applicableUs
LevofloxacinTablet, film coated750 mg/1OralPhysicians Total Care, Inc.2011-06-22Not applicableUs
LevofloxacinTablet, film coated750 mg/1OralAurobindo Pharma Limited2011-06-20Not applicableUs
LevofloxacinTablet, film coated750 mg/1OralLucid Pharma Llc2011-06-20Not applicableUs
LevofloxacinTablet, film coated250 mg/1OralA S Medication Solutions2011-06-20Not applicableUs
LevofloxacinTablet, film coated500 mg/1OralJubilant Cadista Pharmaceuticals Inc.2012-12-02Not applicableUs
LevofloxacinTablet750 mg/1OralMajor Pharmaceuticals2011-06-23Not applicableUs
LevofloxacinTablet, film coated500 mg/1OralClinical Solutions Wholesale2011-06-20Not applicableUs
LevofloxacinTablet250 mg/1OralHikma Pharmaceutical2011-06-21Not applicableUs
LevofloxacinTablet, film coated750 mg/1OralA S Medication Solutions2011-06-20Not applicableUs
LevofloxacinTablet, film coated250 mg/1OralDr. Reddy's Laboratories Limited2011-06-20Not applicableUs
LevofloxacinTablet, film coated500 mg/1Oralbryant ranch prepack2011-06-20Not applicableUs
LevofloxacinTablet, film coated750 mg/1OralAmerican Health Packaging2011-07-01Not applicableUs
LevofloxacinTablet, film coated500 mg/1OralSTAT Rx USA LLC2011-08-13Not applicableUs
LevofloxacinTablet, film coated500 mg/1OralNorthwind Pharmaceuticals2014-03-03Not applicableUs
LevofloxacinTablet, film coated500 mg/1OralREMEDYREPACK INC.2016-01-07Not applicableUs
LevofloxacinTablet, film coated500 mg/1OralAv Kare, Inc.2013-07-122016-10-13Us
LevofloxacinTablet, film coated750 mg/1OralCamber Pharmaceuticals, Inc.2015-01-09Not applicableUs
LevofloxacinTablet750 mg/1OralAidarex Pharmaceuticals LLC2011-06-20Not applicableUs
LevofloxacinTablet, film coated250 mg/1OralSandoz Inc2011-06-20Not applicableUs
LevofloxacinTablet250 mg/1OralWest ward Pharmaceutical Corp2011-06-21Not applicableUs
LevofloxacinTablet, film coated500 mg/1OralREMEDYREPACK INC.2013-09-19Not applicableUs
LevofloxacinTablet250 mg/1OralWockhardt Limited2011-06-20Not applicableUs
LevofloxacinTablet, film coated250 mg/1OralZydus Pharmaceuticals (USA) Inc.2012-11-10Not applicableUs
LevofloxacinTablet, film coated750 mg/1OralREMEDYREPACK INC.2016-08-15Not applicableUs
LevofloxacinTablet, film coated750 mg/1OralPreferred Pharamaceuticals, Inc.2016-11-08Not applicableUs
LevofloxacinTablet, film coated500 mg/1OralDIRECT RX2015-01-01Not applicableUs
LevofloxacinTablet500 mg/1OralWockhardt USA LLC.2011-06-20Not applicableUs
LevofloxacinTablet, film coated500 mg/1OralBlenheim Pharmacal, Inc.2014-01-14Not applicableUs
LevofloxacinTablet, film coated500 mg/1OralPd Rx Pharmaceuticals, Inc.2012-03-22Not applicableUs
LevofloxacinTablet, film coated500 mg/1OralH.J. Harkins Company, Inc.2011-11-22Not applicableUs
LevofloxacinTablet, film coated750 mg/1OralProficient Rx LP2011-06-20Not applicableUs
LevofloxacinTablet, film coated750 mg/1OralCadila Healthcare Limited2012-11-10Not applicableUs
LevofloxacinTablet500 mg/1OralTorrent Pharmaceuticals Limited2011-06-20Not applicableUs
LevofloxacinSolution25 mg/mLOralHi Tech Pharmacal Co., Inc.2011-06-21Not applicableUs
LevofloxacinTablet, film coated750 mg/1OralCentral Texas Community Health Centers2012-03-22Not applicableUs
LevofloxacinTablet, film coated250 mg/1OralLake Erie Medical DBA Quality Care Products LLC2011-06-20Not applicableUs
LevofloxacinInjection, solution5 mg/mLIntravenousSagent Pharmaceuticals2011-06-20Not applicableUs
LevofloxacinInjection, solution5 mg/mLIntravenousSandoz Inc2011-07-07Not applicableUs
LevofloxacinTablet, film coated500 mg/1OralCardinal Health2013-12-01Not applicableUs
LevofloxacinTablet, film coated500 mg/1OralCitron Pharma LLC2011-06-20Not applicableUs
LevofloxacinInjection, solution500 mg/100mLIntravenousAuro Medics Pharma Llc2016-02-10Not applicableUs
LevofloxacinTablet750 mg/1OralCipla USA Inc.2012-03-30Not applicableUs
LevofloxacinTablet, film coated500 mg/1OralDIRECT RX2015-01-01Not applicableUs
LevofloxacinTablet, film coated500 mg/1OralBoca Pharmacal, LLC2012-08-17Not applicableUs
LevofloxacinTablet, film coated750 mg/1OralBlenheim Pharmacal, Inc.2013-11-15Not applicableUs
LevofloxacinTablet, film coated500 mg/1OralPd Rx Pharmaceuticals, Inc.2011-06-20Not applicableUs
LevofloxacinTablet750 mg/1OralPreferred Pharmaceuticals, Inc.2013-03-27Not applicableUs
LevofloxacinInjection25 mg/mLIntravenousHeritage Pharmaceuticals Inc.2013-02-04Not applicableUs
LevofloxacinInjection, solution750 mg/150mLIntravenousWest Ward Pharmaceuticals Corp2011-09-16Not applicableUs
LevofloxacinTablet, film coated750 mg/1OralTeva Pharmaceuticals USA Inc2011-06-202016-06-30Us
LevofloxacinInjection, solution5 mg/mLIntravenousClaris Lifesciences Inc.2013-07-01Not applicableUs
LevofloxacinTablet750 mg/1OralCardinal Health2011-06-23Not applicableUs
LevofloxacinTablet, film coated250 mg/1OralLupin Pharmaceuticals, Inc.2011-06-20Not applicableUs
LevofloxacinTablet, film coated500 mg/1OralA S Medication Solutions2011-06-20Not applicableUs
LevofloxacinTablet, film coated750 mg/1OralA S Medication Solutions2012-08-17Not applicableUs
LevofloxacinTablet, film coated250 mg/1OralREMEDYREPACK INC.2013-03-08Not applicableUs
LevofloxacinInjection, solution5 mg/mLIntravenousWG Critical Care, LLC2016-04-14Not applicableUs
LevofloxacinTablet, film coated750 mg/1OralAv Kare, Inc.2013-07-122016-10-13Us
LevofloxacinTablet, film coated250 mg/1OralMacleods Pharmaceuticals Limited2012-03-22Not applicableUs
LevofloxacinTablet, film coated250 mg/1OralMajor Pharmaceuticals2013-12-01Not applicableUs
LevofloxacinTablet, film coated750 mg/1OralREMEDYREPACK INC.2015-04-29Not applicableUs
LevofloxacinTablet500 mg/1OralHikma Pharmaceutical2011-06-21Not applicableUs
LevofloxacinTablet, film coated250 mg/1OralA S Medication Solutions2011-06-20Not applicableUs
LevofloxacinTablet, film coated500 mg/1OralDr. Reddy's Laboratories Limited2011-06-20Not applicableUs
LevofloxacinTablet, film coated750 mg/1Oralbryant ranch prepack2011-06-20Not applicableUs
LevofloxacinTablet, film coated750 mg/1OralPreferred Pharmaceuticals, Inc.2011-06-20Not applicableUs
LevofloxacinInjection25 mg/mLIntravenousAkorn, Inc.2011-07-01Not applicableUs
LevofloxacinTablet, film coated500 mg/1OralPd Rx Pharmaceuticals, Inc.2012-03-22Not applicableUs
LevofloxacinTablet250 mg/1OralAidarex Pharmaceuticals LLC2011-06-20Not applicableUs
LevofloxacinTablet, film coated500 mg/1OralSandoz Inc2011-06-20Not applicableUs
LevofloxacinInjection, solution5 mg/mLIntravenousHospira, Inc.2015-09-032016-10-13Us
LevofloxacinTablet, film coated250 mg/1OralREMEDYREPACK INC.2013-12-31Not applicableUs
LevofloxacinTablet500 mg/1OralWockhardt Limited2011-06-20Not applicableUs
LevofloxacinTablet, film coated500 mg/1OralZydus Pharmaceuticals (USA) Inc.2012-11-10Not applicableUs
LevofloxacinTablet, film coated500 mg/1OralLake Erie Medical DBA Quality Care Products LLC2011-06-20Not applicableUs
LevofloxacinTablet, film coated500 mg/1OralProficient Rx2011-06-20Not applicableUs
LevofloxacinTablet750 mg/1OralWockhardt USA LLC.2011-06-20Not applicableUs
LevofloxacinTablet, film coated750 mg/1OralBlenheim Pharmacal, Inc.2015-03-26Not applicableUs
LevofloxacinTablet, film coated750 mg/1OralProficient Rx LP2012-11-10Not applicableUs
LevofloxacinTablet, film coated250 mg/1OralAmerican Health Packaging2011-07-01Not applicableUs
LevofloxacinTablet750 mg/1OralTorrent Pharmaceuticals Limited2011-06-20Not applicableUs
LevofloxacinTablet, film coated500 mg/1OralUnit Dose Services2011-06-20Not applicableUs
LevofloxacinTablet, film coated500 mg/1OralProficient Rx LP2012-03-22Not applicableUs
LevofloxacinTablet, film coated500 mg/1OralLake Erie Medical DBA Quality Care Products LLC2011-06-20Not applicableUs
LevofloxacinTablet, film coated250 mg/1OralCamber Pharmaceuticals, Inc.2015-01-09Not applicableUs
LevofloxacinTablet250 mg/1OralMajor Pharmaceuticals2011-06-23Not applicableUs
LevofloxacinTablet, film coated750 mg/1OralCardinal Health2013-12-01Not applicableUs
LevofloxacinTablet, film coated750 mg/1OralCitron Pharma LLC2011-06-20Not applicableUs
LevofloxacinInjection, solution750 mg/150mLIntravenousAuro Medics Pharma Llc2016-02-10Not applicableUs
LevofloxacinTablet500 mg/1OralCipla USA Inc.2012-03-30Not applicableUs
LevofloxacinTablet, film coated750 mg/1OralREMEDYREPACK INC.2016-10-26Not applicableUs
LevofloxacinTablet750 mg/1OralDIRECT RX2015-01-01Not applicableUs
LevofloxacinTablet, film coated750 mg/1OralBoca Pharmacal, LLC2012-08-17Not applicableUs
LevofloxacinTablet, film coated500 mg/1OralBlenheim Pharmacal, Inc.2015-07-15Not applicableUs
LevofloxacinTablet, film coated750 mg/1OralPd Rx Pharmaceuticals, Inc.2011-06-20Not applicableUs
LevofloxacinTablet, film coated500 mg/1OralPreferred Pharmaceuticals, Inc.2011-08-12Not applicableUs
LevofloxacinInjection, solution25 mg/mLIntravenousSagent Pharmaceuticals2012-01-05Not applicableUs
LevofloxacinInjection, solution500 mg/100mLIntravenousWest Ward Pharmaceuticals Corp2011-09-16Not applicableUs
LevofloxacinTablet750 mg/1OralWest ward Pharmaceutical Corp2011-06-21Not applicableUs
LevofloxacinInjection, solution5 mg/mLIntravenousClaris Lifesciences Inc.2013-07-01Not applicableUs
LevofloxacinTablet500 mg/1OralCardinal Health2011-06-23Not applicableUs
LevofloxacinTablet, film coated500 mg/1OralLupin Pharmaceuticals, Inc.2011-06-20Not applicableUs
LevofloxacinTablet, film coated750 mg/1OralA S Medication Solutions2012-08-17Not applicableUs
LevofloxacinTablet, film coated250 mg/1OralPhysicians Total Care, Inc.2011-09-15Not applicableUs
LevofloxacinInjection, solution5 mg/mLIntravenousWG Critical Care, LLC2016-04-14Not applicableUs
LevofloxacinTablet, film coated500 mg/1OralPd Rx Pharmaceuticals, Inc.2011-06-20Not applicableUs
LevofloxacinTablet, film coated500 mg/1OralMacleods Pharmaceuticals Limited2012-03-22Not applicableUs
LevofloxacinTablet, film coated500 mg/1OralMajor Pharmaceuticals2013-12-01Not applicableUs
LevofloxacinTablet, film coated250 mg/1OralAurobindo Pharma Limited2011-06-20Not applicableUs
LevofloxacinTablet750 mg/1OralHikma Pharmaceutical2011-06-21Not applicableUs
LevofloxacinTablet, film coated250 mg/1OralLucid Pharma Llc2011-06-20Not applicableUs
LevofloxacinTablet, film coated750 mg/1OralDr. Reddy's Laboratories Limited2011-06-20Not applicableUs
LevofloxacinTablet250 mg/1Oralbryant ranch prepack2011-06-20Not applicableUs
LevofloxacinTablet, film coated500 mg/1OralPreferred Pharmaceuticals, Inc.2011-06-20Not applicableUs
LevofloxacinTablet, film coated250 mg/1OralRebel Distributors Corp2011-06-20Not applicableUs
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
CravitNot Available
ElequineNot Available
FloxelNot Available
LeroxacinNot Available
LevokacinNot Available
LevoxNot Available
LevoxacinNot Available
MosardalNot Available
NofaxinNot Available
ReskuinNot Available
TavanicNot Available
Brand mixturesNot Available
Salts
Name/CASStructureProperties
Levofloxacin hemihydrate
138199-71-0
Thumb
  • InChI Key: SUIQUYDRLGGZOL-RCWTXCDDSA-N
  • Monoisotopic Mass: 740.298133282
  • Average Mass: 740.762
DBSALT001001
Categories
UNIIRIX4E89Y14
CAS number100986-85-4
WeightAverage: 361.3675
Monoisotopic: 361.143784348
Chemical FormulaC18H20FN3O4
InChI KeyGSDSWSVVBLHKDQ-JTQLQIEISA-N
InChI
InChI=1S/C18H20FN3O4/c1-10-9-26-17-14-11(16(23)12(18(24)25)8-22(10)14)7-13(19)15(17)21-5-3-20(2)4-6-21/h7-8,10H,3-6,9H2,1-2H3,(H,24,25)/t10-/m0/s1
IUPAC Name
(2S)-7-fluoro-2-methyl-6-(4-methylpiperazin-1-yl)-10-oxo-4-oxa-1-azatricyclo[7.3.1.0⁵,¹³]trideca-5(13),6,8,11-tetraene-11-carboxylic acid
SMILES
C[[email protected]]1COC2=C3N1C=C(C(O)=O)C(=O)C3=CC(F)=C2N1CCN(C)CC1
Pharmacology
IndicationFor the treatment of bacterial conjunctivitis caused by susceptible strains of the following organisms: Corynebacterium species, Staphylococus aureus, Staphylococcus epidermidis, Streptococcus pneumoniae, Streptococcus (Groups C/F/G), Viridans group streptococci, Acinetobacter lwoffii, Haemophilus influenzae, Serratia marcescens.
Structured Indications
PharmacodynamicsLevofloxacin, a fluoroquinolone antiinfective, is the optically active L-isomer of ofloxacin. Levofloxacin is used to treat bacterial conjunctivitis, sinusitis, chronic bronchitis, community-acquired pneumonia and pneumonia caused by penicillin-resistant strains of Streptococcus pneumoniae, skin and skin structure infections, complicated urinary tract infections and acute pyelonephritis.
Mechanism of actionLevofloxacin inhibits bacterial type II topoisomerases, topoisomerase IV and DNA gyrase. Levofloxacin, like other fluoroquinolones, inhibits the A subunits of DNA gyrase, two subunits encoded by the gyrA gene. This results in strand breakage on a bacterial chromosome, supercoiling, and resealing; DNA replication and transcription is inhibited.
TargetKindPharmacological actionActionsOrganismUniProt ID
DNA gyrase subunit AProteinyes
inhibitor
Haemophilus influenzae (strain ATCC 51907 / DSM 11121 / KW20 / Rd)P43700 details
DNA topoisomerase 4 subunit AProteinyes
inhibitor
Haemophilus influenzae (strain ATCC 51907 / DSM 11121 / KW20 / Rd)P43702 details
DNA topoisomerase 2-alphaProteinyes
inhibitor
HumanP11388 details
Related Articles
AbsorptionAbsorption of ofloxacin after single or multiple doses of 200 to 400 mg is predictable, and the amount of drug absorbed increases proportionately with the dose.
Volume of distributionNot Available
Protein binding24-38% (to plasma proteins)
Metabolism

Mainly excreted as unchanged drug (87%); undergoes limited metabolism in humans.

Route of eliminationMainly excreted as unchanged drug in the urine.
Half life6-8 hours
ClearanceNot Available
ToxicitySide effects include disorientation, dizziness, drowsiness, hot and cold flashes, nausea, slurring of speech, swelling and numbness in the face
Affected organisms
  • Enteric bacteria and other eubacteria
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
Interactions
Drug Interactions
DrugInteractionDrug group
16-BromoepiandrosteroneThe risk or severity of adverse effects can be increased when 16-Bromoepiandrosterone is combined with Levofloxacin.Investigational
19-norandrostenedioneThe risk or severity of adverse effects can be increased when 19-norandrostenedione is combined with Levofloxacin.Experimental, Illicit
4-AndrostenedioneThe risk or severity of adverse effects can be increased when 4-Androstenedione is combined with Levofloxacin.Experimental, Illicit
5-androstenedioneThe risk or severity of adverse effects can be increased when 5-androstenedione is combined with Levofloxacin.Experimental, Illicit
AcarboseLevofloxacin may increase the hypoglycemic activities of Acarbose.Approved, Investigational
AcebutololThe serum concentration of Acebutolol can be increased when it is combined with Levofloxacin.Approved
AceclofenacAceclofenac may increase the neuroexcitatory activities of Levofloxacin.Approved
AcenocoumarolLevofloxacin may increase the anticoagulant activities of Acenocoumarol.Approved
AcetaminophenThe serum concentration of Levofloxacin can be increased when it is combined with Acetaminophen.Approved
AcetovanilloneAcetovanillone may increase the neuroexcitatory activities of Levofloxacin.Investigational
AcetyldigitoxinAcetyldigitoxin may decrease the cardiotoxic activities of Levofloxacin.Approved
Acetylsalicylic acidAcetylsalicylic acid may increase the neuroexcitatory activities of Levofloxacin.Approved, Vet Approved
AdapaleneAdapalene may increase the neuroexcitatory activities of Levofloxacin.Approved
AfatinibThe serum concentration of Afatinib can be increased when it is combined with Levofloxacin.Approved
AlbendazoleThe serum concentration of Levofloxacin can be increased when it is combined with Albendazole.Approved, Vet Approved
AlbiglutideLevofloxacin may increase the hypoglycemic activities of Albiglutide.Approved
AlclometasoneThe risk or severity of adverse effects can be increased when Alclometasone is combined with Levofloxacin.Approved
AldosteroneThe risk or severity of adverse effects can be increased when Aldosterone is combined with Levofloxacin.Experimental
AlectinibThe serum concentration of Levofloxacin can be increased when it is combined with Alectinib.Approved
AlfentanilThe serum concentration of Levofloxacin can be increased when it is combined with Alfentanil.Approved, Illicit
AlfuzosinAlfuzosin may increase the QTc-prolonging activities of Levofloxacin.Approved, Investigational
AlitretinoinThe serum concentration of Alitretinoin can be increased when it is combined with Levofloxacin.Approved, Investigational
AlogliptinLevofloxacin may increase the hypoglycemic activities of Alogliptin.Approved
Aluminum hydroxideAluminum hydroxide can cause a decrease in the absorption of Levofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Aluminum phosphateAluminum phosphate can cause a decrease in the absorption of Levofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
AmantadineAmantadine may increase the QTc-prolonging activities of Levofloxacin.Approved
AmbrisentanThe serum concentration of Ambrisentan can be increased when it is combined with Levofloxacin.Approved, Investigational
Ambroxol acefyllinateThe metabolism of Ambroxol acefyllinate can be decreased when combined with Levofloxacin.Experimental
AmcinonideThe risk or severity of adverse effects can be increased when Amcinonide is combined with Levofloxacin.Approved
Aminohippuric acidThe serum concentration of Levofloxacin can be increased when it is combined with Aminohippuric acid.Approved
AminophyllineThe metabolism of Aminophylline can be decreased when combined with Levofloxacin.Approved
AmiodaroneLevofloxacin may increase the QTc-prolonging activities of Amiodarone.Approved, Investigational
AmitriptylineAmitriptyline may increase the QTc-prolonging activities of Levofloxacin.Approved
AmlodipineThe serum concentration of Levofloxacin can be increased when it is combined with Amlodipine.Approved
AmoxapineAmoxapine may increase the QTc-prolonging activities of Levofloxacin.Approved
AmprenavirThe serum concentration of Levofloxacin can be decreased when it is combined with Amprenavir.Approved
AmsacrineThe serum concentration of Levofloxacin can be increased when it is combined with Amsacrine.Approved
AnagrelideLevofloxacin may increase the QTc-prolonging activities of Anagrelide.Approved
AnecortaveThe risk or severity of adverse effects can be increased when Anecortave is combined with Levofloxacin.Investigational
AnisodamineAnisodamine may increase the neuroexcitatory activities of Levofloxacin.Investigational
AntipyrineAntipyrine may increase the neuroexcitatory activities of Levofloxacin.Approved
AnvirzelAnvirzel may decrease the cardiotoxic activities of Levofloxacin.Investigational
ApixabanThe serum concentration of Apixaban can be increased when it is combined with Levofloxacin.Approved
ApomorphineApomorphine may increase the QTc-prolonging activities of Levofloxacin.Approved, Investigational
ApremilastApremilast may increase the neuroexcitatory activities of Levofloxacin.Approved, Investigational
ArformoterolArformoterol may increase the QTc-prolonging activities of Levofloxacin.Approved, Investigational
AripiprazoleAripiprazole may increase the QTc-prolonging activities of Levofloxacin.Approved, Investigational
Arsenic trioxideLevofloxacin may increase the QTc-prolonging activities of Arsenic trioxide.Approved, Investigational
ArtemetherLevofloxacin may increase the QTc-prolonging activities of Artemether.Approved
AsenapineLevofloxacin may increase the QTc-prolonging activities of Asenapine.Approved
AstemizoleThe serum concentration of Levofloxacin can be increased when it is combined with Astemizole.Approved, Withdrawn
AtazanavirAtazanavir may increase the QTc-prolonging activities of Levofloxacin.Approved, Investigational
AtenololThe serum concentration of Levofloxacin can be increased when it is combined with Atenolol.Approved
AtomoxetineAtomoxetine may increase the QTc-prolonging activities of Levofloxacin.Approved
AtorvastatinThe serum concentration of Levofloxacin can be increased when it is combined with Atorvastatin.Approved
AxitinibThe serum concentration of Axitinib can be increased when it is combined with Levofloxacin.Approved, Investigational
AzapropazoneAzapropazone may increase the neuroexcitatory activities of Levofloxacin.Withdrawn
AzelastineAzelastine may increase the neuroexcitatory activities of Levofloxacin.Approved
AzithromycinAzithromycin may increase the QTc-prolonging activities of Levofloxacin.Approved
BalsalazideBalsalazide may increase the neuroexcitatory activities of Levofloxacin.Approved, Investigational
BcgThe therapeutic efficacy of Bcg can be decreased when used in combination with Levofloxacin.Investigational
BeclomethasoneThe risk or severity of adverse effects can be increased when Beclomethasone is combined with Levofloxacin.Investigational
Beclomethasone dipropionateThe risk or severity of adverse effects can be increased when Beclomethasone dipropionate is combined with Levofloxacin.Approved, Investigational
BedaquilineLevofloxacin may increase the QTc-prolonging activities of Bedaquiline.Approved
BenoxaprofenBenoxaprofen may increase the neuroexcitatory activities of Levofloxacin.Withdrawn
BenzocaineThe serum concentration of Levofloxacin can be increased when it is combined with Benzocaine.Approved
BepridilThe serum concentration of Levofloxacin can be increased when it is combined with Bepridil.Approved, Withdrawn
BetamethasoneThe risk or severity of adverse effects can be increased when Betamethasone is combined with Levofloxacin.Approved, Vet Approved
BetamethasoneThe serum concentration of Betamethasone can be increased when it is combined with Levofloxacin.Approved, Vet Approved
Betulinic AcidBetulinic Acid may increase the neuroexcitatory activities of Levofloxacin.Investigational
BevacizumabBevacizumab may increase the cardiotoxic activities of Levofloxacin.Approved, Investigational
BiperidenThe serum concentration of Levofloxacin can be increased when it is combined with Biperiden.Approved
Bismuth SubcitrateBismuth Subcitrate can cause a decrease in the absorption of Levofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
BoceprevirThe serum concentration of Boceprevir can be increased when it is combined with Levofloxacin.Approved
BortezomibBortezomib may increase the QTc-prolonging activities of Levofloxacin.Approved, Investigational
BosutinibThe serum concentration of Bosutinib can be increased when it is combined with Levofloxacin.Approved
Brentuximab vedotinThe serum concentration of Brentuximab vedotin can be increased when it is combined with Levofloxacin.Approved
BromfenacBromfenac may increase the neuroexcitatory activities of Levofloxacin.Approved
BromocriptineThe serum concentration of Levofloxacin can be increased when it is combined with Bromocriptine.Approved, Investigational
BucillamineBucillamine may increase the neuroexcitatory activities of Levofloxacin.Investigational
BudesonideThe risk or severity of adverse effects can be increased when Budesonide is combined with Levofloxacin.Approved
BuprenorphineThe serum concentration of Levofloxacin can be increased when it is combined with Buprenorphine.Approved, Illicit, Investigational, Vet Approved
BuserelinBuserelin may increase the QTc-prolonging activities of Levofloxacin.Approved
BuspironeThe serum concentration of Levofloxacin can be increased when it is combined with Buspirone.Approved, Investigational
CabazitaxelThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Levofloxacin.Approved
CaffeineThe serum concentration of Caffeine can be increased when it is combined with Levofloxacin.Approved
CalciumCalcium can cause a decrease in the absorption of Levofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Nutraceutical
Calcium AcetateCalcium Acetate can cause a decrease in the absorption of Levofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Calcium carbonateCalcium carbonate can cause a decrease in the absorption of Levofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Calcium ChlorideCalcium Chloride can cause a decrease in the absorption of Levofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Calcium citrateCalcium citrate can cause a decrease in the absorption of Levofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Calcium glubionateCalcium glubionate can cause a decrease in the absorption of Levofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Calcium GluceptateCalcium Gluceptate can cause a decrease in the absorption of Levofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Calcium gluconateCalcium gluconate can cause a decrease in the absorption of Levofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Vet Approved
CamptothecinThe serum concentration of Camptothecin can be increased when it is combined with Levofloxacin.Experimental
CanagliflozinThe serum concentration of Canagliflozin can be increased when it is combined with Levofloxacin.Approved
CandesartanThe serum concentration of Levofloxacin can be increased when it is combined with Candesartan.Approved
CaptoprilThe serum concentration of Levofloxacin can be increased when it is combined with Captopril.Approved
CarbamazepineThe serum concentration of Levofloxacin can be decreased when it is combined with Carbamazepine.Approved, Investigational
CarfilzomibThe serum concentration of Carfilzomib can be increased when it is combined with Levofloxacin.Approved
CarprofenCarprofen may increase the neuroexcitatory activities of Levofloxacin.Approved, Vet Approved, Withdrawn
CarvedilolThe serum concentration of Levofloxacin can be increased when it is combined with Carvedilol.Approved, Investigational
CaspofunginThe serum concentration of Levofloxacin can be increased when it is combined with Caspofungin.Approved
CastanospermineCastanospermine may increase the neuroexcitatory activities of Levofloxacin.Experimental
CelecoxibCelecoxib may increase the neuroexcitatory activities of Levofloxacin.Approved, Investigational
CeritinibLevofloxacin may increase the QTc-prolonging activities of Ceritinib.Approved
CerivastatinThe serum concentration of Cerivastatin can be increased when it is combined with Levofloxacin.Withdrawn
ChloroquineChloroquine may increase the QTc-prolonging activities of Levofloxacin.Approved, Vet Approved
ChlorpromazineChlorpromazine may increase the QTc-prolonging activities of Levofloxacin.Approved, Vet Approved
ChlorpropamideThe serum concentration of Levofloxacin can be increased when it is combined with Chlorpropamide.Approved
ChlorprothixeneThe serum concentration of Levofloxacin can be increased when it is combined with Chlorprothixene.Approved, Withdrawn
CholesterolThe serum concentration of Levofloxacin can be increased when it is combined with Cholesterol.Experimental
Cholic AcidThe serum concentration of Levofloxacin can be decreased when it is combined with Cholic Acid.Approved
CiclesonideThe risk or severity of adverse effects can be increased when Ciclesonide is combined with Levofloxacin.Approved, Investigational
CilazaprilThe serum concentration of Levofloxacin can be increased when it is combined with Cilazapril.Approved
CimetidineThe serum concentration of Levofloxacin can be decreased when it is combined with Cimetidine.Approved
CiprofloxacinCiprofloxacin may increase the QTc-prolonging activities of Levofloxacin.Approved, Investigational
CisaprideLevofloxacin may increase the QTc-prolonging activities of Cisapride.Approved, Investigational, Withdrawn
CisplatinThe serum concentration of Cisplatin can be increased when it is combined with Levofloxacin.Approved
CitalopramLevofloxacin may increase the QTc-prolonging activities of Citalopram.Approved
ClarithromycinLevofloxacin may increase the QTc-prolonging activities of Clarithromycin.Approved
ClobazamThe serum concentration of Clobazam can be increased when it is combined with Levofloxacin.Approved, Illicit
ClobetasolThe risk or severity of adverse effects can be increased when Clobetasol is combined with Levofloxacin.Investigational
Clobetasol propionateThe risk or severity of adverse effects can be increased when Clobetasol propionate is combined with Levofloxacin.Approved
ClocortoloneThe risk or severity of adverse effects can be increased when Clocortolone is combined with Levofloxacin.Approved
ClofazimineThe serum concentration of Levofloxacin can be increased when it is combined with Clofazimine.Approved, Investigational
ClomifeneThe serum concentration of Clomifene can be increased when it is combined with Levofloxacin.Approved, Investigational
ClomipramineClomipramine may increase the QTc-prolonging activities of Levofloxacin.Approved, Vet Approved
ClonidineThe serum concentration of Clonidine can be increased when it is combined with Levofloxacin.Approved
ClonixinClonixin may increase the neuroexcitatory activities of Levofloxacin.Approved
ClopidogrelThe serum concentration of Clopidogrel can be increased when it is combined with Levofloxacin.Approved, Nutraceutical
ClotrimazoleThe serum concentration of Levofloxacin can be decreased when it is combined with Clotrimazole.Approved, Vet Approved
ClozapineClozapine may increase the QTc-prolonging activities of Levofloxacin.Approved
CobicistatThe serum concentration of Levofloxacin can be increased when it is combined with Cobicistat.Approved
CobimetinibThe serum concentration of Cobimetinib can be increased when it is combined with Levofloxacin.Approved
ColchicineThe serum concentration of Colchicine can be increased when it is combined with Levofloxacin.Approved
ColforsinThe serum concentration of Levofloxacin can be increased when it is combined with Colforsin.Experimental
Conjugated Equine EstrogensThe serum concentration of Conjugated Equine Estrogens can be increased when it is combined with Levofloxacin.Approved
Cortisone acetateThe risk or severity of adverse effects can be increased when Cortisone acetate is combined with Levofloxacin.Approved
CrizotinibLevofloxacin may increase the QTc-prolonging activities of Crizotinib.Approved
CurcuminCurcumin may increase the neuroexcitatory activities of Levofloxacin.Investigational
CyclophosphamideCyclophosphamide may increase the cardiotoxic activities of Levofloxacin.Approved, Investigational
CyclosporineThe serum concentration of Levofloxacin can be decreased when it is combined with Cyclosporine.Approved, Investigational, Vet Approved
D-LimoneneD-Limonene may increase the neuroexcitatory activities of Levofloxacin.Investigational
Dabigatran etexilateThe serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Levofloxacin.Approved
DabrafenibDabrafenib may increase the QTc-prolonging activities of Levofloxacin.Approved
DaclatasvirThe serum concentration of Levofloxacin can be increased when it is combined with Daclatasvir.Approved
DactinomycinThe serum concentration of Levofloxacin can be increased when it is combined with Dactinomycin.Approved
DapagliflozinThe serum concentration of Dapagliflozin can be increased when it is combined with Levofloxacin.Approved
DasatinibDasatinib may increase the QTc-prolonging activities of Levofloxacin.Approved, Investigational
DaunorubicinThe serum concentration of Levofloxacin can be decreased when it is combined with Daunorubicin.Approved
DebrisoquinThe serum concentration of Debrisoquin can be increased when it is combined with Levofloxacin.Approved
DegarelixDegarelix may increase the QTc-prolonging activities of Levofloxacin.Approved
dehydroepiandrosterone sulfateThe risk or severity of adverse effects can be increased when dehydroepiandrosterone sulfate is combined with Levofloxacin.Investigational
DesfluraneDesflurane may increase the QTc-prolonging activities of Levofloxacin.Approved
DesipramineDesipramine may increase the QTc-prolonging activities of Levofloxacin.Approved
DeslanosideDeslanoside may decrease the cardiotoxic activities of Levofloxacin.Approved
DesloratadineThe serum concentration of Levofloxacin can be increased when it is combined with Desloratadine.Approved, Investigational
DesoximetasoneThe risk or severity of adverse effects can be increased when Desoximetasone is combined with Levofloxacin.Approved
Desoxycorticosterone acetateThe risk or severity of adverse effects can be increased when Desoxycorticosterone acetate is combined with Levofloxacin.Approved
Desoxycorticosterone PivalateThe risk or severity of adverse effects can be increased when Desoxycorticosterone Pivalate is combined with Levofloxacin.Experimental, Vet Approved
DexamethasoneThe risk or severity of adverse effects can be increased when Dexamethasone is combined with Levofloxacin.Approved, Investigational, Vet Approved
Dexamethasone isonicotinateThe risk or severity of adverse effects can be increased when Dexamethasone isonicotinate is combined with Levofloxacin.Vet Approved
DextromethorphanThe serum concentration of Levofloxacin can be increased when it is combined with Dextromethorphan.Approved
DiazepamThe serum concentration of Diazepam can be increased when it is combined with Levofloxacin.Approved, Illicit, Vet Approved
DiclofenacDiclofenac may increase the neuroexcitatory activities of Levofloxacin.Approved, Vet Approved
DicoumarolLevofloxacin may increase the anticoagulant activities of Dicoumarol.Approved
DidanosineThe serum concentration of Didanosine can be decreased when it is combined with Levofloxacin.Approved
DiethylstilbestrolThe serum concentration of Diethylstilbestrol can be increased when it is combined with Levofloxacin.Approved
DiflorasoneThe risk or severity of adverse effects can be increased when Diflorasone is combined with Levofloxacin.Approved
DiflunisalDiflunisal may increase the neuroexcitatory activities of Levofloxacin.Approved
DifluocortoloneThe risk or severity of adverse effects can be increased when Difluocortolone is combined with Levofloxacin.Approved
DifluprednateThe risk or severity of adverse effects can be increased when Difluprednate is combined with Levofloxacin.Approved
DigitoxinDigitoxin may decrease the cardiotoxic activities of Levofloxacin.Approved
DigoxinDigoxin may decrease the cardiotoxic activities of Levofloxacin.Approved
DihydroergotamineThe serum concentration of Levofloxacin can be increased when it is combined with Dihydroergotamine.Approved
DihydrotestosteroneThe serum concentration of Dihydrotestosterone can be increased when it is combined with Levofloxacin.Illicit
DiltiazemThe serum concentration of Levofloxacin can be increased when it is combined with Diltiazem.Approved
DiphenhydramineDiphenhydramine may increase the QTc-prolonging activities of Levofloxacin.Approved
DipyridamoleThe serum concentration of Levofloxacin can be increased when it is combined with Dipyridamole.Approved
DisopyramideLevofloxacin may increase the QTc-prolonging activities of Disopyramide.Approved
DocetaxelThe risk or severity of adverse effects can be increased when Docetaxel is combined with Levofloxacin.Approved, Investigational
DofetilideLevofloxacin may increase the QTc-prolonging activities of Dofetilide.Approved
DolasetronDolasetron may increase the QTc-prolonging activities of Levofloxacin.Approved
DomperidoneLevofloxacin may increase the QTc-prolonging activities of Domperidone.Approved, Investigational, Vet Approved
DoxazosinThe serum concentration of Levofloxacin can be increased when it is combined with Doxazosin.Approved
DoxepinDoxepin may increase the QTc-prolonging activities of Levofloxacin.Approved
DoxorubicinThe serum concentration of Doxorubicin can be increased when it is combined with Levofloxacin.Approved, Investigational
DoxorubicinThe serum concentration of Levofloxacin can be decreased when it is combined with Doxorubicin.Approved, Investigational
DronabinolThe serum concentration of Levofloxacin can be increased when it is combined with Dronabinol.Approved, Illicit
DronedaroneLevofloxacin may increase the QTc-prolonging activities of Dronedarone.Approved
DroperidolDroperidol may increase the QTc-prolonging activities of Levofloxacin.Approved, Vet Approved
DroxicamDroxicam may increase the neuroexcitatory activities of Levofloxacin.Approved
DulaglutideLevofloxacin may increase the hypoglycemic activities of Dulaglutide.Approved
DuvelisibDuvelisib may increase the neuroexcitatory activities of Levofloxacin.Investigational
DyphyllineThe metabolism of Dyphylline can be decreased when combined with Levofloxacin.Approved
E6201E6201 may increase the neuroexcitatory activities of Levofloxacin.Investigational
EbselenEbselen may increase the neuroexcitatory activities of Levofloxacin.Investigational
EdoxabanThe serum concentration of Edoxaban can be increased when it is combined with Levofloxacin.Approved
ElbasvirThe serum concentration of Levofloxacin can be increased when it is combined with Elbasvir.Approved
EletriptanThe serum concentration of Eletriptan can be increased when it is combined with Levofloxacin.Approved, Investigational
EliglustatLevofloxacin may increase the QTc-prolonging activities of Eliglustat.Approved
EmpagliflozinLevofloxacin may increase the hypoglycemic activities of Empagliflozin.Approved
EnalaprilThe serum concentration of Levofloxacin can be increased when it is combined with Enalapril.Approved, Vet Approved
EnzalutamideThe serum concentration of Levofloxacin can be increased when it is combined with Enzalutamide.Approved
EpinastineThe serum concentration of Epinastine can be increased when it is combined with Levofloxacin.Approved, Investigational
EpirizoleEpirizole may increase the neuroexcitatory activities of Levofloxacin.Approved
EquileninThe risk or severity of adverse effects can be increased when Equilenin is combined with Levofloxacin.Experimental
EquilinThe risk or severity of adverse effects can be increased when Equilin is combined with Levofloxacin.Approved
ErgonovineThe serum concentration of Levofloxacin can be increased when it is combined with Ergonovine.Approved
ErgotamineThe serum concentration of Levofloxacin can be increased when it is combined with Ergotamine.Approved
EribulinEribulin may increase the QTc-prolonging activities of Levofloxacin.Approved, Investigational
ErlotinibThe serum concentration of Erlotinib can be increased when it is combined with Levofloxacin.Approved, Investigational
ErythromycinErythromycin may increase the QTc-prolonging activities of Levofloxacin.Approved, Vet Approved
EscitalopramLevofloxacin may increase the QTc-prolonging activities of Escitalopram.Approved, Investigational
EstradiolThe serum concentration of Estradiol can be increased when it is combined with Levofloxacin.Approved, Investigational, Vet Approved
EstramustineThe serum concentration of Levofloxacin can be increased when it is combined with Estramustine.Approved
EstriolThe serum concentration of Levofloxacin can be decreased when it is combined with Estriol.Approved, Vet Approved
EstroneThe risk or severity of adverse effects can be increased when Estrone is combined with Levofloxacin.Approved
Estrone sulfateThe risk or severity of adverse effects can be increased when Estrone sulfate is combined with Levofloxacin.Approved
EtanerceptEtanercept may increase the neuroexcitatory activities of Levofloxacin.Approved, Investigational
Ethinyl EstradiolThe serum concentration of Ethinyl Estradiol can be increased when it is combined with Levofloxacin.Approved
Ethyl biscoumacetateLevofloxacin may increase the anticoagulant activities of Ethyl biscoumacetate.Withdrawn
EtodolacEtodolac may increase the neuroexcitatory activities of Levofloxacin.Approved, Investigational, Vet Approved
EtofenamateEtofenamate may increase the neuroexcitatory activities of Levofloxacin.Approved
EtoposideThe serum concentration of Levofloxacin can be increased when it is combined with Etoposide.Approved
EtoricoxibEtoricoxib may increase the neuroexcitatory activities of Levofloxacin.Approved, Investigational
EtravirineThe serum concentration of Levofloxacin can be increased when it is combined with Etravirine.Approved
Evening primrose oilEvening primrose oil may increase the neuroexcitatory activities of Levofloxacin.Approved
EverolimusThe serum concentration of Everolimus can be increased when it is combined with Levofloxacin.Approved
ExenatideLevofloxacin may increase the hypoglycemic activities of Exenatide.Approved, Investigational
exisulindexisulind may increase the neuroexcitatory activities of Levofloxacin.Investigational
EzetimibeThe serum concentration of Ezetimibe can be increased when it is combined with Levofloxacin.Approved
EzogabineEzogabine may increase the QTc-prolonging activities of Levofloxacin.Approved
FamotidineFamotidine may increase the QTc-prolonging activities of Levofloxacin.Approved
FelbamateFelbamate may increase the QTc-prolonging activities of Levofloxacin.Approved
FelodipineThe serum concentration of Levofloxacin can be increased when it is combined with Felodipine.Approved, Investigational
FenbufenFenbufen may increase the neuroexcitatory activities of Levofloxacin.Approved
FenoprofenFenoprofen may increase the neuroexcitatory activities of Levofloxacin.Approved
FentanylThe serum concentration of Levofloxacin can be increased when it is combined with Fentanyl.Approved, Illicit, Investigational, Vet Approved
Ferric CarboxymaltoseThe serum concentration of Levofloxacin can be decreased when it is combined with Ferric Carboxymaltose.Approved
Ferric CitrateThe serum concentration of Levofloxacin can be decreased when it is combined with Ferric Citrate.Approved
Ferric pyrophosphateThe serum concentration of Levofloxacin can be decreased when it is combined with Ferric pyrophosphate.Approved
FesoterodineThe serum concentration of Fesoterodine can be increased when it is combined with Levofloxacin.Approved
FexofenadineThe serum concentration of Fexofenadine can be increased when it is combined with Levofloxacin.Approved
FidaxomicinThe serum concentration of Fidaxomicin can be increased when it is combined with Levofloxacin.Approved
FingolimodFingolimod may increase the QTc-prolonging activities of Levofloxacin.Approved, Investigational
FlecainideLevofloxacin may increase the QTc-prolonging activities of Flecainide.Approved, Withdrawn
FloctafenineFloctafenine may increase the neuroexcitatory activities of Levofloxacin.Approved, Withdrawn
fluasteroneThe risk or severity of adverse effects can be increased when fluasterone is combined with Levofloxacin.Investigational
FluconazoleFluconazole may increase the QTc-prolonging activities of Levofloxacin.Approved
FludrocortisoneThe risk or severity of adverse effects can be increased when Fludrocortisone is combined with Levofloxacin.Approved
FluindioneLevofloxacin may increase the anticoagulant activities of Fluindione.Investigational
FlumethasoneThe risk or severity of adverse effects can be increased when Flumethasone is combined with Levofloxacin.Approved, Vet Approved
FlunisolideThe risk or severity of adverse effects can be increased when Flunisolide is combined with Levofloxacin.Approved, Investigational
FlunixinFlunixin may increase the neuroexcitatory activities of Levofloxacin.Vet Approved
Fluocinolone AcetonideThe risk or severity of adverse effects can be increased when Fluocinolone Acetonide is combined with Levofloxacin.Approved, Investigational, Vet Approved
FluocinonideThe risk or severity of adverse effects can be increased when Fluocinonide is combined with Levofloxacin.Approved, Investigational
FluocortoloneThe risk or severity of adverse effects can be increased when Fluocortolone is combined with Levofloxacin.Approved, Withdrawn
FluorometholoneThe risk or severity of adverse effects can be increased when Fluorometholone is combined with Levofloxacin.Approved
FluoxetineLevofloxacin may increase the QTc-prolonging activities of Fluoxetine.Approved, Vet Approved
FlupentixolLevofloxacin may increase the QTc-prolonging activities of Flupentixol.Approved, Withdrawn
FluphenazineThe serum concentration of Levofloxacin can be increased when it is combined with Fluphenazine.Approved
FluprednideneThe risk or severity of adverse effects can be increased when Fluprednidene is combined with Levofloxacin.Approved, Withdrawn
FluprednisoloneThe risk or severity of adverse effects can be increased when Fluprednisolone is combined with Levofloxacin.Approved
FlurandrenolideThe risk or severity of adverse effects can be increased when Flurandrenolide is combined with Levofloxacin.Approved
FlurazepamThe serum concentration of Levofloxacin can be increased when it is combined with Flurazepam.Approved, Illicit
FlurbiprofenFlurbiprofen may increase the neuroexcitatory activities of Levofloxacin.Approved, Investigational
Fluticasone furoateThe risk or severity of adverse effects can be increased when Fluticasone furoate is combined with Levofloxacin.Approved
Fluticasone PropionateThe risk or severity of adverse effects can be increased when Fluticasone Propionate is combined with Levofloxacin.Approved
FluvoxamineThe serum concentration of Levofloxacin can be increased when it is combined with Fluvoxamine.Approved, Investigational
FormestaneThe risk or severity of adverse effects can be increased when Formestane is combined with Levofloxacin.Approved, Investigational, Withdrawn
FormoterolFormoterol may increase the QTc-prolonging activities of Levofloxacin.Approved, Investigational
FoscarnetFoscarnet may increase the QTc-prolonging activities of Levofloxacin.Approved
Gadobenic acidGadobenic acid may increase the QTc-prolonging activities of Levofloxacin.Approved
GalantamineGalantamine may increase the QTc-prolonging activities of Levofloxacin.Approved
GefitinibThe serum concentration of Gefitinib can be increased when it is combined with Levofloxacin.Approved, Investigational
GemcitabineThe serum concentration of Gemcitabine can be increased when it is combined with Levofloxacin.Approved
GemifloxacinLevofloxacin may increase the QTc-prolonging activities of Gemifloxacin.Approved, Investigational
GenisteinThe serum concentration of Levofloxacin can be increased when it is combined with Genistein.Investigational
GliclazideLevofloxacin may increase the hypoglycemic activities of Gliclazide.Approved
GlimepirideLevofloxacin may increase the hypoglycemic activities of Glimepiride.Approved
GlipizideLevofloxacin may increase the hypoglycemic activities of Glipizide.Approved
GlyburideThe serum concentration of Levofloxacin can be increased when it is combined with Glyburide.Approved
GlycerolThe serum concentration of Levofloxacin can be increased when it is combined with Glycerol.Experimental
GoserelinGoserelin may increase the QTc-prolonging activities of Levofloxacin.Approved
Gramicidin DThe serum concentration of Levofloxacin can be increased when it is combined with Gramicidin D.Approved
GranisetronGranisetron may increase the QTc-prolonging activities of Levofloxacin.Approved, Investigational
GrazoprevirThe serum concentration of Grazoprevir can be increased when it is combined with Levofloxacin.Approved
GrepafloxacinThe serum concentration of Grepafloxacin can be increased when it is combined with Levofloxacin.Withdrawn
HaloperidolHaloperidol may increase the QTc-prolonging activities of Levofloxacin.Approved
HE3286The risk or severity of adverse effects can be increased when HE3286 is combined with Levofloxacin.Investigational
HigenamineHigenamine may increase the neuroexcitatory activities of Levofloxacin.Investigational
HistrelinHistrelin may increase the QTc-prolonging activities of Levofloxacin.Approved
HMPL-004HMPL-004 may increase the neuroexcitatory activities of Levofloxacin.Investigational
HydrocortisoneThe risk or severity of adverse effects can be increased when Hydrocortisone is combined with Levofloxacin.Approved, Vet Approved
HydroxyzineHydroxyzine may increase the QTc-prolonging activities of Levofloxacin.Approved
IbandronateIbandronate may increase the QTc-prolonging activities of Levofloxacin.Approved, Investigational
IbuprofenIbuprofen may increase the neuroexcitatory activities of Levofloxacin.Approved
IbuproxamIbuproxam may increase the neuroexcitatory activities of Levofloxacin.Withdrawn
IbutilideLevofloxacin may increase the QTc-prolonging activities of Ibutilide.Approved
IcatibantIcatibant may increase the neuroexcitatory activities of Levofloxacin.Approved
IdelalisibThe serum concentration of Idelalisib can be increased when it is combined with Levofloxacin.Approved
IloperidoneLevofloxacin may increase the QTc-prolonging activities of Iloperidone.Approved
ImatinibThe serum concentration of Imatinib can be increased when it is combined with Levofloxacin.Approved
ImipramineImipramine may increase the QTc-prolonging activities of Levofloxacin.Approved
IndacaterolIndacaterol may increase the QTc-prolonging activities of Levofloxacin.Approved
IndapamideIndapamide may increase the QTc-prolonging activities of Levofloxacin.Approved
IndinavirThe serum concentration of Levofloxacin can be decreased when it is combined with Indinavir.Approved
IndomethacinIndomethacin may increase the neuroexcitatory activities of Levofloxacin.Approved, Investigational
IndoprofenIndoprofen may increase the neuroexcitatory activities of Levofloxacin.Withdrawn
Insulin AspartLevofloxacin may increase the hypoglycemic activities of Insulin Aspart.Approved
Insulin DetemirLevofloxacin may increase the hypoglycemic activities of Insulin Detemir.Approved
Insulin GlargineLevofloxacin may increase the hypoglycemic activities of Insulin Glargine.Approved
Insulin GlulisineLevofloxacin may increase the hypoglycemic activities of Insulin Glulisine.Approved
Insulin HumanLevofloxacin may increase the hypoglycemic activities of Insulin Human.Approved, Investigational
Insulin LisproLevofloxacin may increase the hypoglycemic activities of Insulin Lispro.Approved
IrinotecanThe serum concentration of Irinotecan can be increased when it is combined with Levofloxacin.Approved, Investigational
IronThe serum concentration of Levofloxacin can be decreased when it is combined with Iron.Approved
Iron DextranThe serum concentration of Levofloxacin can be decreased when it is combined with Iron Dextran.Approved, Vet Approved
Iron saccharateThe serum concentration of Levofloxacin can be decreased when it is combined with Iron saccharate.Approved
IsavuconazoniumThe serum concentration of Levofloxacin can be increased when it is combined with Isavuconazonium.Approved, Investigational
IsofluraneIsoflurane may increase the QTc-prolonging activities of Levofloxacin.Approved, Vet Approved
IsoxicamIsoxicam may increase the neuroexcitatory activities of Levofloxacin.Withdrawn
IsradipineIsradipine may increase the QTc-prolonging activities of Levofloxacin.Approved
IstaroximeThe risk or severity of adverse effects can be increased when Istaroxime is combined with Levofloxacin.Investigational
ItraconazoleItraconazole may increase the QTc-prolonging activities of Levofloxacin.Approved, Investigational
IvabradineIvabradine may increase the QTc-prolonging activities of Levofloxacin.Approved
IvacaftorThe serum concentration of Levofloxacin can be increased when it is combined with Ivacaftor.Approved
IvermectinThe serum concentration of Levofloxacin can be increased when it is combined with Ivermectin.Approved, Vet Approved
KebuzoneKebuzone may increase the neuroexcitatory activities of Levofloxacin.Experimental
KetamineThe serum concentration of Levofloxacin can be increased when it is combined with Ketamine.Approved, Vet Approved
KetazolamThe serum concentration of Ketazolam can be increased when it is combined with Levofloxacin.Approved
KetoconazoleKetoconazole may increase the QTc-prolonging activities of Levofloxacin.Approved, Investigational
KetoprofenKetoprofen may increase the neuroexcitatory activities of Levofloxacin.Approved, Vet Approved
KetorolacKetorolac may increase the neuroexcitatory activities of Levofloxacin.Approved
LamivudineThe serum concentration of Lamivudine can be increased when it is combined with Levofloxacin.Approved, Investigational
LamotrigineThe serum concentration of Lamotrigine can be increased when it is combined with Levofloxacin.Approved, Investigational
LanreotideLevofloxacin may increase the hypoglycemic activities of Lanreotide.Approved
LansoprazoleThe serum concentration of Levofloxacin can be increased when it is combined with Lansoprazole.Approved, Investigational
Lanthanum carbonateThe serum concentration of Levofloxacin can be decreased when it is combined with Lanthanum carbonate.Approved
LapatinibLapatinib may increase the QTc-prolonging activities of Levofloxacin.Approved, Investigational
LedipasvirThe serum concentration of Ledipasvir can be increased when it is combined with Levofloxacin.Approved
LeflunomideLeflunomide may increase the neuroexcitatory activities of Levofloxacin.Approved, Investigational
LenalidomideThe serum concentration of Lenalidomide can be increased when it is combined with Levofloxacin.Approved
LenvatinibLevofloxacin may increase the QTc-prolonging activities of Lenvatinib.Approved
LeuprolideLeuprolide may increase the QTc-prolonging activities of Levofloxacin.Approved, Investigational
LevetiracetamThe serum concentration of Levetiracetam can be increased when it is combined with Levofloxacin.Approved, Investigational
LevomilnacipranThe serum concentration of Levomilnacipran can be increased when it is combined with Levofloxacin.Approved
LevothyroxineThe serum concentration of Levofloxacin can be decreased when it is combined with Levothyroxine.Approved
LidocaineThe serum concentration of Levofloxacin can be increased when it is combined with Lidocaine.Approved, Vet Approved
LinagliptinThe serum concentration of Linagliptin can be increased when it is combined with Levofloxacin.Approved
LiothyronineThe serum concentration of Levofloxacin can be decreased when it is combined with Liothyronine.Approved, Vet Approved
LiotrixThe serum concentration of Levofloxacin can be decreased when it is combined with Liotrix.Approved
LiraglutideLevofloxacin may increase the hypoglycemic activities of Liraglutide.Approved
LisinoprilThe serum concentration of Levofloxacin can be increased when it is combined with Lisinopril.Approved, Investigational
LisofyllineLisofylline may increase the neuroexcitatory activities of Levofloxacin.Investigational
LithiumLithium may increase the QTc-prolonging activities of Levofloxacin.Approved
LomitapideThe serum concentration of Levofloxacin can be increased when it is combined with Lomitapide.Approved
LoperamideThe serum concentration of Levofloxacin can be increased when it is combined with Loperamide.Approved
LopinavirLevofloxacin may increase the QTc-prolonging activities of Lopinavir.Approved
LoratadineThe serum concentration of Levofloxacin can be increased when it is combined with Loratadine.Approved
LornoxicamLornoxicam may increase the neuroexcitatory activities of Levofloxacin.Approved
LosartanThe serum concentration of Levofloxacin can be increased when it is combined with Losartan.Approved
LovastatinThe serum concentration of Levofloxacin can be increased when it is combined with Lovastatin.Approved, Investigational
LoxoprofenLoxoprofen may increase the neuroexcitatory activities of Levofloxacin.Approved
LumacaftorThe serum concentration of Levofloxacin can be decreased when it is combined with Lumacaftor.Approved
LumefantrineLevofloxacin may increase the QTc-prolonging activities of Lumefantrine.Approved
LumiracoxibLumiracoxib may increase the neuroexcitatory activities of Levofloxacin.Approved, Investigational
MagaldrateMagaldrate can cause a decrease in the absorption of Levofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Withdrawn
Magnesium carbonateMagnesium carbonate can cause a decrease in the absorption of Levofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Magnesium hydroxideMagnesium hydroxide can cause a decrease in the absorption of Levofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Magnesium oxideMagnesium oxide can cause a decrease in the absorption of Levofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Magnesium salicylateThe serum concentration of Levofloxacin can be decreased when it is combined with Magnesium salicylate.Approved
Magnesium SulfateThe serum concentration of Levofloxacin can be decreased when it is combined with Magnesium Sulfate.Approved, Vet Approved
Magnesium TrisilicateMagnesium Trisilicate can cause a decrease in the absorption of Levofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
MannitolThe serum concentration of Mannitol can be increased when it is combined with Levofloxacin.Approved, Investigational
MaprotilineMaprotiline may increase the QTc-prolonging activities of Levofloxacin.Approved
MasoprocolMasoprocol may increase the neuroexcitatory activities of Levofloxacin.Approved
ME-609The risk or severity of adverse effects can be increased when ME-609 is combined with Levofloxacin.Investigational
MebendazoleThe serum concentration of Levofloxacin can be increased when it is combined with Mebendazole.Approved, Vet Approved
MecaserminLevofloxacin may increase the hypoglycemic activities of Mecasermin.Approved, Investigational
Meclofenamic acidMeclofenamic acid may increase the neuroexcitatory activities of Levofloxacin.Approved, Vet Approved
MedrysoneThe risk or severity of adverse effects can be increased when Medrysone is combined with Levofloxacin.Approved
Mefenamic acidMefenamic acid may increase the neuroexcitatory activities of Levofloxacin.Approved
MefloquineMefloquine may increase the QTc-prolonging activities of Levofloxacin.Approved
Megestrol acetateThe serum concentration of Levofloxacin can be increased when it is combined with Megestrol acetate.Approved, Vet Approved
MelengestrolThe risk or severity of adverse effects can be increased when Melengestrol is combined with Levofloxacin.Vet Approved
MeloxicamMeloxicam may increase the neuroexcitatory activities of Levofloxacin.Approved, Vet Approved
MeprobamateThe serum concentration of Levofloxacin can be increased when it is combined with Meprobamate.Approved, Illicit
MesalazineMesalazine may increase the neuroexcitatory activities of Levofloxacin.Approved
MetamizoleMetamizole may increase the neuroexcitatory activities of Levofloxacin.Withdrawn
MetforminLevofloxacin may increase the hypoglycemic activities of Metformin.Approved
MethadoneMethadone may increase the QTc-prolonging activities of Levofloxacin.Approved
MethotrexateThe serum concentration of Methotrexate can be increased when it is combined with Levofloxacin.Approved
MethotrimeprazineMethotrimeprazine may increase the QTc-prolonging activities of Levofloxacin.Approved
MethylprednisoloneThe risk or severity of adverse effects can be increased when Methylprednisolone is combined with Levofloxacin.Approved, Vet Approved
MetoclopramideMetoclopramide may increase the QTc-prolonging activities of Levofloxacin.Approved, Investigational
MetoprololThe serum concentration of Levofloxacin can be increased when it is combined with Metoprolol.Approved, Investigational
MetronidazoleMetronidazole may increase the QTc-prolonging activities of Levofloxacin.Approved
MibefradilThe serum concentration of Levofloxacin can be increased when it is combined with Mibefradil.Withdrawn
MiconazoleThe serum concentration of Levofloxacin can be increased when it is combined with Miconazole.Approved, Investigational, Vet Approved
MidazolamThe serum concentration of Levofloxacin can be decreased when it is combined with Midazolam.Approved, Illicit
MifepristoneMifepristone may increase the QTc-prolonging activities of Levofloxacin.Approved, Investigational
MiglitolLevofloxacin may increase the hypoglycemic activities of Miglitol.Approved
MirabegronMirabegron may increase the QTc-prolonging activities of Levofloxacin.Approved
MirtazapineMirtazapine may increase the QTc-prolonging activities of Levofloxacin.Approved
MitomycinThe serum concentration of Levofloxacin can be increased when it is combined with Mitomycin.Approved
MitoxantroneThe serum concentration of Levofloxacin can be decreased when it is combined with Mitoxantrone.Approved, Investigational
MizoribineMizoribine may increase the neuroexcitatory activities of Levofloxacin.Investigational
MoexiprilMoexipril may increase the QTc-prolonging activities of Levofloxacin.Approved
MometasoneThe risk or severity of adverse effects can be increased when Mometasone is combined with Levofloxacin.Approved, Vet Approved
MorphineThe serum concentration of Levofloxacin can be increased when it is combined with Morphine.Approved, Investigational
MoxifloxacinMoxifloxacin may increase the QTc-prolonging activities of Levofloxacin.Approved, Investigational
Mycophenolate mofetilMycophenolate mofetil may increase the neuroexcitatory activities of Levofloxacin.Approved, Investigational
Mycophenolic acidThe serum concentration of Mycophenolic acid can be decreased when it is combined with Levofloxacin.Approved
NabumetoneNabumetone may increase the neuroexcitatory activities of Levofloxacin.Approved
NadololThe serum concentration of Nadolol can be increased when it is combined with Levofloxacin.Approved
NafamostatNafamostat may increase the neuroexcitatory activities of Levofloxacin.Investigational
NaftifineNaftifine may increase the neuroexcitatory activities of Levofloxacin.Approved
NaloxegolThe serum concentration of Naloxegol can be increased when it is combined with Levofloxacin.Approved
NaloxoneThe serum concentration of Naloxone can be increased when it is combined with Levofloxacin.Approved, Vet Approved
NaltrexoneThe serum concentration of Levofloxacin can be increased when it is combined with Naltrexone.Approved, Investigational, Vet Approved
NaproxenNaproxen may increase the neuroexcitatory activities of Levofloxacin.Approved, Vet Approved
NaringeninThe serum concentration of Levofloxacin can be increased when it is combined with Naringenin.Experimental
NateglinideLevofloxacin may increase the hypoglycemic activities of Nateglinide.Approved, Investigational
NCX 1022The risk or severity of adverse effects can be increased when NCX 1022 is combined with Levofloxacin.Investigational
NCX 4016NCX 4016 may increase the neuroexcitatory activities of Levofloxacin.Investigational
NefazodoneThe serum concentration of Levofloxacin can be decreased when it is combined with Nefazodone.Approved, Withdrawn
NelfinavirNelfinavir may increase the QTc-prolonging activities of Levofloxacin.Approved
NeostigmineThe serum concentration of Levofloxacin can be increased when it is combined with Neostigmine.Approved, Vet Approved
NepafenacNepafenac may increase the neuroexcitatory activities of Levofloxacin.Approved
NicardipineNicardipine may increase the QTc-prolonging activities of Levofloxacin.Approved
NifedipineThe serum concentration of Levofloxacin can be decreased when it is combined with Nifedipine.Approved
Niflumic AcidNiflumic Acid may increase the neuroexcitatory activities of Levofloxacin.Approved
NilotinibLevofloxacin may increase the QTc-prolonging activities of Nilotinib.Approved, Investigational
NimesulideNimesulide may increase the neuroexcitatory activities of Levofloxacin.Approved, Withdrawn
NintedanibThe serum concentration of Nintedanib can be increased when it is combined with Levofloxacin.Approved
NisoldipineThe serum concentration of Levofloxacin can be increased when it is combined with Nisoldipine.Approved
NitrazepamThe serum concentration of Levofloxacin can be increased when it is combined with Nitrazepam.Approved
NitrendipineThe serum concentration of Levofloxacin can be increased when it is combined with Nitrendipine.Approved
NitroaspirinNitroaspirin may increase the neuroexcitatory activities of Levofloxacin.Investigational
NizatidineThe serum concentration of Nizatidine can be increased when it is combined with Levofloxacin.Approved
NorethisteroneThe serum concentration of Levofloxacin can be decreased when it is combined with Norethisterone.Approved
NorfloxacinNorfloxacin may increase the QTc-prolonging activities of Levofloxacin.Approved
NortriptylineNortriptyline may increase the QTc-prolonging activities of Levofloxacin.Approved
OctreotideOctreotide may increase the QTc-prolonging activities of Levofloxacin.Approved, Investigational
OfloxacinLevofloxacin may increase the QTc-prolonging activities of Ofloxacin.Approved
OlanzapineOlanzapine may increase the QTc-prolonging activities of Levofloxacin.Approved, Investigational
Oleoyl estroneThe risk or severity of adverse effects can be increased when Oleoyl estrone is combined with Levofloxacin.Investigational
OlodaterolOlodaterol may increase the QTc-prolonging activities of Levofloxacin.Approved
OlopatadineOlopatadine may increase the neuroexcitatory activities of Levofloxacin.Approved
OlsalazineOlsalazine may increase the neuroexcitatory activities of Levofloxacin.Approved
OmbitasvirThe serum concentration of Ombitasvir can be increased when it is combined with Levofloxacin.Approved
OmeprazoleThe serum concentration of Levofloxacin can be increased when it is combined with Omeprazole.Approved, Investigational, Vet Approved
OndansetronOndansetron may increase the QTc-prolonging activities of Levofloxacin.Approved
OrgoteinOrgotein may increase the neuroexcitatory activities of Levofloxacin.Vet Approved
OsimertinibThe serum concentration of Osimertinib can be increased when it is combined with Levofloxacin.Approved
OuabainOuabain may decrease the cardiotoxic activities of Levofloxacin.Approved
OxaprozinOxaprozin may increase the neuroexcitatory activities of Levofloxacin.Approved
OxyphenbutazoneOxyphenbutazone may increase the neuroexcitatory activities of Levofloxacin.Withdrawn
OxytocinOxytocin may increase the QTc-prolonging activities of Levofloxacin.Approved, Vet Approved
P-NitrophenolThe serum concentration of Levofloxacin can be increased when it is combined with P-Nitrophenol.Experimental
PaclitaxelThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Levofloxacin.Approved, Vet Approved
PaliperidoneLevofloxacin may increase the QTc-prolonging activities of Paliperidone.Approved
Palmitic AcidThe serum concentration of Levofloxacin can be increased when it is combined with Palmitic Acid.Experimental
PanobinostatLevofloxacin may increase the QTc-prolonging activities of Panobinostat.Approved, Investigational
PantoprazoleThe serum concentration of Levofloxacin can be increased when it is combined with Pantoprazole.Approved
ParamethasoneThe risk or severity of adverse effects can be increased when Paramethasone is combined with Levofloxacin.Approved
ParecoxibParecoxib may increase the neuroexcitatory activities of Levofloxacin.Approved
ParoxetineParoxetine may increase the QTc-prolonging activities of Levofloxacin.Approved, Investigational
PasireotidePasireotide may increase the QTc-prolonging activities of Levofloxacin.Approved
PazopanibThe serum concentration of Pazopanib can be increased when it is combined with Levofloxacin.Approved
PentamidinePentamidine may increase the QTc-prolonging activities of Levofloxacin.Approved
PerflutrenPerflutren may increase the QTc-prolonging activities of Levofloxacin.Approved
PerindoprilThe serum concentration of Levofloxacin can be increased when it is combined with Perindopril.Approved
PhenindioneLevofloxacin may increase the anticoagulant activities of Phenindione.Approved
PhenobarbitalThe serum concentration of Levofloxacin can be decreased when it is combined with Phenobarbital.Approved
PhenprocoumonLevofloxacin may increase the anticoagulant activities of Phenprocoumon.Approved
PhenylbutazonePhenylbutazone may increase the neuroexcitatory activities of Levofloxacin.Approved, Vet Approved
PhenytoinThe serum concentration of Phenytoin can be increased when it is combined with Levofloxacin.Approved, Vet Approved
Picosulfuric acidThe therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Levofloxacin.Approved
PimecrolimusPimecrolimus may increase the neuroexcitatory activities of Levofloxacin.Approved, Investigational
PimozideLevofloxacin may increase the QTc-prolonging activities of Pimozide.Approved
PioglitazoneLevofloxacin may increase the hypoglycemic activities of Pioglitazone.Approved, Investigational
PirfenidonePirfenidone may increase the neuroexcitatory activities of Levofloxacin.Investigational
PiroxicamPiroxicam may increase the neuroexcitatory activities of Levofloxacin.Approved, Investigational
PitavastatinThe serum concentration of Pitavastatin can be increased when it is combined with Levofloxacin.Approved
Platelet Activating FactorThe serum concentration of Levofloxacin can be decreased when it is combined with Platelet Activating Factor.Experimental
PomalidomideThe serum concentration of Pomalidomide can be increased when it is combined with Levofloxacin.Approved
PonatinibThe serum concentration of Ponatinib can be increased when it is combined with Levofloxacin.Approved
PosaconazolePosaconazole may increase the QTc-prolonging activities of Levofloxacin.Approved, Investigational, Vet Approved
PramlintideLevofloxacin may increase the hypoglycemic activities of Pramlintide.Approved, Investigational
PrasteroneThe risk or severity of adverse effects can be increased when Prasterone is combined with Levofloxacin.Approved, Nutraceutical
PravastatinThe serum concentration of Pravastatin can be increased when it is combined with Levofloxacin.Approved
PrazosinThe serum concentration of Levofloxacin can be increased when it is combined with Prazosin.Approved
PrednicarbateThe risk or severity of adverse effects can be increased when Prednicarbate is combined with Levofloxacin.Approved
PrednisoloneThe risk or severity of adverse effects can be increased when Prednisolone is combined with Levofloxacin.Approved, Vet Approved
PrednisoneThe risk or severity of adverse effects can be increased when Prednisone is combined with Levofloxacin.Approved, Vet Approved
PregnenoloneThe risk or severity of adverse effects can be increased when Pregnenolone is combined with Levofloxacin.Experimental
PrimaquinePrimaquine may increase the QTc-prolonging activities of Levofloxacin.Approved
ProbenecidThe serum concentration of Levofloxacin can be increased when it is combined with Probenecid.Approved
ProcainamideLevofloxacin may increase the QTc-prolonging activities of Procainamide.Approved
ProgesteroneThe serum concentration of Levofloxacin can be decreased when it is combined with Progesterone.Approved, Vet Approved
PromazinePromazine may increase the QTc-prolonging activities of Levofloxacin.Approved, Vet Approved
PromethazinePromethazine may increase the QTc-prolonging activities of Levofloxacin.Approved
PropacetamolPropacetamol may increase the neuroexcitatory activities of Levofloxacin.Approved
PropafenoneLevofloxacin may increase the QTc-prolonging activities of Propafenone.Approved
PropofolPropofol may increase the QTc-prolonging activities of Levofloxacin.Approved, Investigational, Vet Approved
PropranololThe serum concentration of Propranolol can be increased when it is combined with Levofloxacin.Approved, Investigational
ProtriptylineProtriptyline may increase the QTc-prolonging activities of Levofloxacin.Approved
PrucaloprideThe serum concentration of Prucalopride can be increased when it is combined with Levofloxacin.Approved
PTC299PTC299 may increase the neuroexcitatory activities of Levofloxacin.Investigational
QuercetinThe serum concentration of Levofloxacin can be increased when it is combined with Quercetin.Experimental
QuetiapineLevofloxacin may increase the QTc-prolonging activities of Quetiapine.Approved
QuinacrineThe serum concentration of Levofloxacin can be increased when it is combined with Quinacrine.Approved
QuinaprilThe serum concentration of Levofloxacin can be decreased when it is combined with Quinapril.Approved, Investigational
QuinidineLevofloxacin may increase the QTc-prolonging activities of Quinidine.Approved
QuinineLevofloxacin may increase the QTc-prolonging activities of Quinine.Approved
RanitidineThe serum concentration of Levofloxacin can be increased when it is combined with Ranitidine.Approved
RanolazineThe serum concentration of Ranolazine can be increased when it is combined with Levofloxacin.Approved, Investigational
ReboxetineThe serum concentration of Levofloxacin can be increased when it is combined with Reboxetine.Approved, Investigational
RegorafenibThe serum concentration of Levofloxacin can be increased when it is combined with Regorafenib.Approved
RepaglinideLevofloxacin may increase the hypoglycemic activities of Repaglinide.Approved, Investigational
ReserpineThe serum concentration of Levofloxacin can be decreased when it is combined with Reserpine.Approved
ResveratrolResveratrol may increase the neuroexcitatory activities of Levofloxacin.Experimental, Investigational
RifampicinThe serum concentration of Levofloxacin can be decreased when it is combined with Rifampicin.Approved
RifaximinThe serum concentration of Rifaximin can be increased when it is combined with Levofloxacin.Approved, Investigational
RilpivirineRilpivirine may increase the QTc-prolonging activities of Levofloxacin.Approved
RimexoloneThe risk or severity of adverse effects can be increased when Rimexolone is combined with Levofloxacin.Approved
RisperidoneRisperidone may increase the QTc-prolonging activities of Levofloxacin.Approved, Investigational
RitonavirRitonavir may increase the QTc-prolonging activities of Levofloxacin.Approved, Investigational
RivaroxabanThe serum concentration of Rivaroxaban can be increased when it is combined with Levofloxacin.Approved
RofecoxibRofecoxib may increase the neuroexcitatory activities of Levofloxacin.Investigational, Withdrawn
RolapitantThe serum concentration of Levofloxacin can be increased when it is combined with Rolapitant.Approved
RomidepsinThe serum concentration of Romidepsin can be increased when it is combined with Levofloxacin.Approved, Investigational
RosiglitazoneLevofloxacin may increase the hypoglycemic activities of Rosiglitazone.Approved, Investigational
SalbutamolSalbutamol may increase the QTc-prolonging activities of Levofloxacin.Approved, Vet Approved
SalicylamideSalicylamide may increase the neuroexcitatory activities of Levofloxacin.Approved
Salicylic acidSalicylic acid may increase the neuroexcitatory activities of Levofloxacin.Approved, Vet Approved
SalmeterolSalmeterol may increase the QTc-prolonging activities of Levofloxacin.Approved
SalsalateSalsalate may increase the neuroexcitatory activities of Levofloxacin.Approved
SaquinavirLevofloxacin may increase the QTc-prolonging activities of Saquinavir.Approved, Investigational
SaxagliptinLevofloxacin may increase the hypoglycemic activities of Saxagliptin.Approved
ScopolamineThe serum concentration of Levofloxacin can be increased when it is combined with Scopolamine.Approved
SelegilineThe serum concentration of Levofloxacin can be increased when it is combined with Selegiline.Approved, Investigational, Vet Approved
SelexipagThe serum concentration of Selexipag can be increased when it is combined with Levofloxacin.Approved
SeratrodastSeratrodast may increase the neuroexcitatory activities of Levofloxacin.Approved, Investigational
SertralineSertraline may increase the QTc-prolonging activities of Levofloxacin.Approved
SevelamerSevelamer can cause a decrease in the absorption of Levofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
SevofluraneSevoflurane may increase the QTc-prolonging activities of Levofloxacin.Approved, Vet Approved
SilodosinThe serum concentration of Silodosin can be increased when it is combined with Levofloxacin.Approved
SimeprevirThe serum concentration of Simeprevir can be increased when it is combined with Levofloxacin.Approved
SimvastatinThe serum concentration of Levofloxacin can be increased when it is combined with Simvastatin.Approved
SirolimusThe serum concentration of Levofloxacin can be decreased when it is combined with Sirolimus.Approved, Investigational
SitagliptinThe serum concentration of Sitagliptin can be increased when it is combined with Levofloxacin.Approved, Investigational
SofosbuvirThe serum concentration of Sofosbuvir can be increased when it is combined with Levofloxacin.Approved
SolifenacinSolifenacin may increase the QTc-prolonging activities of Levofloxacin.Approved
SorafenibSorafenib may increase the QTc-prolonging activities of Levofloxacin.Approved, Investigational
SotalolLevofloxacin may increase the QTc-prolonging activities of Sotalol.Approved
SparfloxacinThe serum concentration of Sparfloxacin can be increased when it is combined with Levofloxacin.Approved
SphingosineThe serum concentration of Sphingosine can be increased when it is combined with Levofloxacin.Experimental
SpironolactoneThe serum concentration of Levofloxacin can be increased when it is combined with Spironolactone.Approved
SRT501SRT501 may increase the neuroexcitatory activities of Levofloxacin.Investigational
St. John's WortThe serum concentration of Levofloxacin can be decreased when it is combined with St. John's Wort.Nutraceutical
StaurosporineThe serum concentration of Levofloxacin can be increased when it is combined with Staurosporine.Experimental
StreptozocinThe serum concentration of Levofloxacin can be decreased when it is combined with Streptozocin.Approved
Strontium ranelateThe serum concentration of Levofloxacin can be decreased when it is combined with Strontium ranelate.Approved
SucralfateThe serum concentration of Levofloxacin can be decreased when it is combined with Sucralfate.Approved
SulfadiazineLevofloxacin may increase the hypoglycemic activities of Sulfadiazine.Approved, Vet Approved
SulfamethoxazoleSulfamethoxazole may increase the QTc-prolonging activities of Levofloxacin.Approved
SulfasalazineSulfasalazine may increase the neuroexcitatory activities of Levofloxacin.Approved
SulfinpyrazoneThe serum concentration of Levofloxacin can be increased when it is combined with Sulfinpyrazone.Approved
SulfisoxazoleSulfisoxazole may increase the QTc-prolonging activities of Levofloxacin.Approved, Vet Approved
SulindacSulindac may increase the neuroexcitatory activities of Levofloxacin.Approved
SumatriptanThe serum concentration of Levofloxacin can be increased when it is combined with Sumatriptan.Approved, Investigational
SunitinibSunitinib may increase the QTc-prolonging activities of Levofloxacin.Approved, Investigational
SuprofenSuprofen may increase the neuroexcitatory activities of Levofloxacin.Approved, Withdrawn
TacrineThe serum concentration of Levofloxacin can be increased when it is combined with Tacrine.Withdrawn
TacrolimusThe serum concentration of Levofloxacin can be decreased when it is combined with Tacrolimus.Approved, Investigational
TacrolimusLevofloxacin may increase the QTc-prolonging activities of Tacrolimus.Approved, Investigational
TamoxifenTamoxifen may increase the QTc-prolonging activities of Levofloxacin.Approved
Taurocholic AcidThe serum concentration of Levofloxacin can be increased when it is combined with Taurocholic Acid.Experimental
Technetium Tc-99m sestamibiThe serum concentration of Technetium Tc-99m sestamibi can be increased when it is combined with Levofloxacin.Approved
TelaprevirThe serum concentration of Telaprevir can be increased when it is combined with Levofloxacin.Approved
TelavancinLevofloxacin may increase the QTc-prolonging activities of Telavancin.Approved
TelithromycinTelithromycin may increase the QTc-prolonging activities of Levofloxacin.Approved
TelmisartanThe serum concentration of Levofloxacin can be increased when it is combined with Telmisartan.Approved, Investigational
TemsirolimusThe serum concentration of Temsirolimus can be increased when it is combined with Levofloxacin.Approved
TenoxicamTenoxicam may increase the neuroexcitatory activities of Levofloxacin.Approved
TepoxalinTepoxalin may increase the neuroexcitatory activities of Levofloxacin.Vet Approved
TerazosinThe serum concentration of Levofloxacin can be increased when it is combined with Terazosin.Approved
TerbutalineTerbutaline may increase the QTc-prolonging activities of Levofloxacin.Approved
TerfenadineThe serum concentration of Levofloxacin can be increased when it is combined with Terfenadine.Withdrawn
TeriflunomideThe serum concentration of Levofloxacin can be increased when it is combined with Teriflunomide.Approved
TesmilifeneThe serum concentration of Levofloxacin can be decreased when it is combined with Tesmilifene.Investigational
TestosteroneThe serum concentration of Levofloxacin can be increased when it is combined with Testosterone.Approved, Investigational
TetrabenazineLevofloxacin may increase the QTc-prolonging activities of Tetrabenazine.Approved
TheophyllineThe metabolism of Theophylline can be decreased when combined with Levofloxacin.Approved
ThioridazineLevofloxacin may increase the QTc-prolonging activities of Thioridazine.Approved
ThiothixeneThiothixene may increase the QTc-prolonging activities of Levofloxacin.Approved
Tiaprofenic acidTiaprofenic acid may increase the neuroexcitatory activities of Levofloxacin.Approved
TicagrelorThe serum concentration of Ticagrelor can be increased when it is combined with Levofloxacin.Approved
TimololThe serum concentration of Timolol can be increased when it is combined with Levofloxacin.Approved
TinoridineTinoridine may increase the neuroexcitatory activities of Levofloxacin.Investigational
TixocortolThe risk or severity of adverse effects can be increased when Tixocortol is combined with Levofloxacin.Approved
TizanidineTizanidine may increase the QTc-prolonging activities of Levofloxacin.Approved
TolazamideLevofloxacin may increase the hypoglycemic activities of Tolazamide.Approved
TolbutamideLevofloxacin may increase the hypoglycemic activities of Tolbutamide.Approved
Tolfenamic AcidTolfenamic Acid may increase the neuroexcitatory activities of Levofloxacin.Approved
TolmetinTolmetin may increase the neuroexcitatory activities of Levofloxacin.Approved
TolterodineTolterodine may increase the QTc-prolonging activities of Levofloxacin.Approved, Investigational
TolvaptanThe serum concentration of Tolvaptan can be increased when it is combined with Levofloxacin.Approved
TopotecanThe serum concentration of Topotecan can be increased when it is combined with Levofloxacin.Approved, Investigational
ToremifeneLevofloxacin may increase the QTc-prolonging activities of Toremifene.Approved, Investigational
TranilastTranilast may increase the neuroexcitatory activities of Levofloxacin.Approved, Investigational
TrastuzumabTrastuzumab may increase the cardiotoxic activities of Levofloxacin.Approved, Investigational
Trastuzumab emtansineThe serum concentration of Trastuzumab emtansine can be increased when it is combined with Levofloxacin.Approved
TrazodoneTrazodone may increase the QTc-prolonging activities of Levofloxacin.Approved, Investigational
TreprostinilTreprostinil may increase the QTc-prolonging activities of Levofloxacin.Approved, Investigational
TriamcinoloneThe risk or severity of adverse effects can be increased when Triamcinolone is combined with Levofloxacin.Approved, Vet Approved
TrifluoperazineThe serum concentration of Levofloxacin can be increased when it is combined with Trifluoperazine.Approved
TriflupromazineThe serum concentration of Levofloxacin can be increased when it is combined with Triflupromazine.Approved, Vet Approved
TrimethoprimTrimethoprim may increase the QTc-prolonging activities of Levofloxacin.Approved, Vet Approved
TrimipramineTrimipramine may increase the QTc-prolonging activities of Levofloxacin.Approved
TriptorelinTriptorelin may increase the QTc-prolonging activities of Levofloxacin.Approved, Vet Approved
Trisalicylate-cholineTrisalicylate-choline may increase the neuroexcitatory activities of Levofloxacin.Approved
TroleandomycinThe serum concentration of Levofloxacin can be increased when it is combined with Troleandomycin.Approved
UlipristalThe serum concentration of Ulipristal can be increased when it is combined with Levofloxacin.Approved
UmeclidiniumThe serum concentration of Umeclidinium can be increased when it is combined with Levofloxacin.Approved
ValdecoxibValdecoxib may increase the neuroexcitatory activities of Levofloxacin.Investigational, Withdrawn
VandetanibLevofloxacin may increase the QTc-prolonging activities of Vandetanib.Approved
VardenafilVardenafil may increase the QTc-prolonging activities of Levofloxacin.Approved
VareniclineThe serum concentration of Varenicline can be increased when it is combined with Levofloxacin.Approved, Investigational
VecuroniumThe serum concentration of Vecuronium can be increased when it is combined with Levofloxacin.Approved
VemurafenibLevofloxacin may increase the QTc-prolonging activities of Vemurafenib.Approved
VenetoclaxThe serum concentration of Venetoclax can be increased when it is combined with Levofloxacin.Approved
VenlafaxineVenlafaxine may increase the QTc-prolonging activities of Levofloxacin.Approved
VerapamilThe serum concentration of Levofloxacin can be decreased when it is combined with Verapamil.Approved
VilanterolVilanterol may increase the QTc-prolonging activities of Levofloxacin.Approved
VinblastineThe serum concentration of Levofloxacin can be decreased when it is combined with Vinblastine.Approved
VincristineThe serum concentration of Vincristine can be increased when it is combined with Levofloxacin.Approved, Investigational
VincristineThe serum concentration of Levofloxacin can be decreased when it is combined with Vincristine.Approved, Investigational
VinorelbineThe serum concentration of Levofloxacin can be increased when it is combined with Vinorelbine.Approved, Investigational
VismodegibThe serum concentration of Vismodegib can be increased when it is combined with Levofloxacin.Approved
VoriconazoleVoriconazole may increase the QTc-prolonging activities of Levofloxacin.Approved, Investigational
VorinostatVorinostat may increase the QTc-prolonging activities of Levofloxacin.Approved, Investigational
WarfarinLevofloxacin may increase the anticoagulant activities of Warfarin.Approved
ZaltoprofenZaltoprofen may increase the neuroexcitatory activities of Levofloxacin.Approved
ZidovudineThe serum concentration of Zidovudine can be increased when it is combined with Levofloxacin.Approved
ZileutonZileuton may increase the neuroexcitatory activities of Levofloxacin.Approved, Investigational, Withdrawn
ZimelidineThe serum concentration of Levofloxacin can be increased when it is combined with Zimelidine.Withdrawn
ZiprasidoneLevofloxacin may increase the QTc-prolonging activities of Ziprasidone.Approved
ZomepiracZomepirac may increase the neuroexcitatory activities of Levofloxacin.Withdrawn
ZuclopenthixolLevofloxacin may increase the QTc-prolonging activities of Zuclopenthixol.Approved, Investigational
Food Interactions
  • Take without regard to meals. Take with water, drink lliberally. Taking this product with orange juice can result in reduced quinolone plasma levels.
References
Synthesis Reference

Valerie Niddam-Hildesheim, “Preparation of levofloxacin and forms thereof.” U.S. Patent US20030130507, issued July 10, 2003.

US20030130507
General ReferencesNot Available
External Links
ATC CodesA02BD10J01RA05S01AE05J01MA12
AHFS Codes
  • 08:12.18
PDB EntriesNot Available
FDA labelDownload (139 KB)
MSDSNot Available
ADMET
Predicted ADMET featuresNot Available
Pharmacoeconomics
ManufacturersNot Available
Packagers
Dosage forms
FormRouteStrength
SolutionOphthalmic15 mg/mL
SolutionIntravenous25 mg
InjectionIntravenous25 mg/mL
InjectionIntravenous5 mg/mL
Injection, solutionIntravenous25 mg/mL
Injection, solutionIntravenous250 mg/50mL
Injection, solutionIntravenous5 mg/mL
Injection, solutionIntravenous500 mg/100mL
Injection, solutionIntravenous750 mg/150mL
Injection, solution, concentrateIntravenous500 mg/20mL
Injection, solution, concentrateIntravenous750 mg/30mL
SolutionOral25 mg/mL
Solution / dropsOphthalmic5 mg/mL
Solution / dropsTopical5 mg/mL
TabletOral250 mg/1
TabletOral500 mg/1
TabletOral750 mg/1
Tablet, film coatedOral250 mg/1
Tablet, film coatedOral500 mg/1
Tablet, film coatedOral750 mg/1
SolutionIntravenous5 mg
TabletOral250 mg
TabletOral500 mg
SolutionRespiratory (inhalation)240 mg
SolutionOphthalmic5 mg/mL
TabletOral750 mg
Prices
Unit descriptionCostUnit
Iquix 1.5% Solution 5ml Bottle81.68USD bottle
Levofloxacin hemihydr 100% powder42.69USD g
Levaquin 750 mg tablet28.06USD each
Levaquin 750 mg leva-pak tablet27.51USD tablet
Levaquin 500 mg tablet16.57USD tablet
Iquix 1.5% eye drops15.71USD ml
Levaquin 250 mg tablet13.71USD tablet
Quixin 0.5% eye drops12.21USD ml
Quixin 0.5% Solution11.4USD ml
Levaquin i.v. 25 mg/ml vial1.94USD ml
Levaquin 500 mg/100 ml d5w0.44USD ml
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US5053407 No1993-12-202010-12-20Us
US6806256 Yes2002-08-262022-08-26Us
Properties
StateSolid
Experimental Properties
PropertyValueSource
water solubilityInsolubleNot Available
logP2.1Not Available
Predicted Properties
PropertyValueSource
Water Solubility1.44 mg/mLALOGPS
logP-0.02ALOGPS
logP0.65ChemAxon
logS-2.4ALOGPS
pKa (Strongest Acidic)5.45ChemAxon
pKa (Strongest Basic)6.2ChemAxon
Physiological Charge-1ChemAxon
Hydrogen Acceptor Count7ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area73.32 Å2ChemAxon
Rotatable Bond Count2ChemAxon
Refractivity94.94 m3·mol-1ChemAxon
Polarizability36.69 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
LC-MS/MSLC-MS/MS Spectrum - Quattro_QQQ 10V, N/A (Annotated)splash10-00gm-1315975420-b0c4e6cdef799fda69b4View in MoNA
LC-MS/MSLC-MS/MS Spectrum - Quattro_QQQ 25V, N/A (Annotated)splash10-0abc-3459425420-e8a4ecd2f8aea93fa660View in MoNA
LC-MS/MSLC-MS/MS Spectrum - Quattro_QQQ 40V, N/A (Annotated)splash10-0h9p-3513893500-1d5c8069419fa2c37ebbView in MoNA
1D NMR1H NMR SpectrumNot Available
2D NMR[1H,13C] 2D NMR SpectrumNot Available
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as quinoline carboxylic acids. These are quinolines in which the quinoline ring system is substituted by a carboxyl group at one or more positions.
KingdomOrganic compounds
Super ClassOrganoheterocyclic compounds
ClassQuinolines and derivatives
Sub ClassQuinoline carboxylic acids
Direct ParentQuinoline carboxylic acids
Alternative Parents
Substituents
  • Quinoline-3-carboxylic acid
  • N-arylpiperazine
  • Fluoroquinolone
  • Hydroxyquinoline
  • Dihydroquinolone
  • Aminoquinoline
  • Dihydroquinoline
  • Benzoxazine
  • Pyridine carboxylic acid or derivatives
  • Pyridine carboxylic acid
  • Dialkylarylamine
  • N-alkylpiperazine
  • N-methylpiperazine
  • Fluorobenzene
  • Alkyl aryl ether
  • Benzenoid
  • Pyridine
  • Piperazine
  • 1,4-diazinane
  • Aryl halide
  • Aryl fluoride
  • Heteroaromatic compound
  • Vinylogous amide
  • Tertiary aliphatic amine
  • Tertiary amine
  • Oxacycle
  • Azacycle
  • Monocarboxylic acid or derivatives
  • Ether
  • Carboxylic acid
  • Carboxylic acid derivative
  • Hydrocarbon derivative
  • Organooxygen compound
  • Organonitrogen compound
  • Organofluoride
  • Organohalogen compound
  • Carbonyl group
  • Amine
  • Aromatic heteropolycyclic compound
Molecular FrameworkAromatic heteropolycyclic compounds
External Descriptors

Targets

Kind
Protein
Organism
Haemophilus influenzae (strain ATCC 51907 / DSM 11121 / KW20 / Rd)
Pharmacological action
yes
Actions
inhibitor
General Function:
Dna topoisomerase type ii (atp-hydrolyzing) activity
Specific Function:
DNA gyrase negatively supercoils closed circular double-stranded DNA in an ATP-dependent manner and also catalyzes the interconversion of other topological isomers of double-stranded DNA rings, including catenanes and knotted rings.
Gene Name:
gyrA
Uniprot ID:
P43700
Molecular Weight:
97817.145 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
  3. Schmitz FJ, Hofmann B, Hansen B, Scheuring S, Luckefahr M, Klootwijk M, Verhoef J, Fluit A, Heinz HP, Kohrer K, Jones ME: Relationship between ciprofloxacin, ofloxacin, levofloxacin, sparfloxacin and moxifloxacin (BAY 12-8039) MICs and mutations in grlA, grlB, gyrA and gyrB in 116 unrelated clinical isolates of Staphylococcus aureus. J Antimicrob Chemother. 1998 Apr;41(4):481-4. [PubMed:9598779 ]
  4. Brisse S, Milatovic D, Fluit AC, Verhoef J, Martin N, Scheuring S, Kohrer K, Schmitz FJ: Comparative in vitro activities of ciprofloxacin, clinafloxacin, gatifloxacin, levofloxacin, moxifloxacin, and trovafloxacin against Klebsiella pneumoniae, Klebsiella oxytoca, Enterobacter cloacae, and Enterobacter aerogenes clinical isolates with alterations in GyrA and ParC proteins. Antimicrob Agents Chemother. 1999 Aug;43(8):2051-5. [PubMed:10428935 ]
  5. Messina C, Cafiso V, Campanile F, Santagati M, Stefani S: Rapid method for detection of gyrA and grlA mutations in unrelated strains of Staphylococci susceptible and resistant to levofloxacin. New Microbiol. 2001 Oct;24(4):347-53. [PubMed:11718372 ]
Kind
Protein
Organism
Haemophilus influenzae (strain ATCC 51907 / DSM 11121 / KW20 / Rd)
Pharmacological action
yes
Actions
inhibitor
General Function:
Dna topoisomerase type ii (atp-hydrolyzing) activity
Specific Function:
Topoisomerase IV is essential for chromosome segregation. It relaxes supercoiled DNA. Performs the decatenation events required during the replication of a circular DNA molecule.
Gene Name:
parC
Uniprot ID:
P43702
Molecular Weight:
83366.24 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
  3. Zheng X, Johnson C, Lu Y, Yanagihara R, Hollingshead S, Crain M, Benjamin W Jr, Waites KB: Clinical isolates of Streptococcus pneumoniae resistant to levofloxacin contain mutations in both gyrA and parC genes. Int J Antimicrob Agents. 2001 Oct;18(4):373-8. [PubMed:11691571 ]
  4. Schafer J, Hovde LB, Simonson D, Rotschafer JC: In vitro pharmacodynamics of moxifloxacin versus levofloxacin against 4 strains of Streptococcus pneumoniae: 1 wild type, 2 first-step parC mutants, and 1 pump mutant. Diagn Microbiol Infect Dis. 2008 Feb;60(2):155-61. Epub 2007 Oct 29. [PubMed:17910998 ]
  5. Deryke CA, Du X, Nicolau DP: Evaluation of bacterial kill when modelling the bronchopulmonary pharmacokinetic profile of moxifloxacin and levofloxacin against parC-containing isolates of Streptococcus pneumoniae. J Antimicrob Chemother. 2006 Sep;58(3):601-9. Epub 2006 Jul 19. [PubMed:16857688 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Ubiquitin binding
Specific Function:
Control of topological states of DNA by transient breakage and subsequent rejoining of DNA strands. Topoisomerase II makes double-strand breaks. Essential during mitosis and meiosis for proper segregation of daughter chromosomes. May play a role in regulating the period length of ARNTL/BMAL1 transcriptional oscillation (By similarity).
Gene Name:
TOP2A
Uniprot ID:
P11388
Molecular Weight:
174383.88 Da
References
  1. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. Most active in catalyzing 2-hydroxylation. Caffeine is metabolized primarily by cytochrome CYP1A2 in the liver through an initial N...
Gene Name:
CYP1A2
Uniprot ID:
P05177
Molecular Weight:
58293.76 Da
References
  1. Bellon A, Perez-Garcia G, Coverdale JH, Chacko RC: Seizures associated with levofloxacin: case presentation and literature review. Eur J Clin Pharmacol. 2009 Oct;65(10):959-62. doi: 10.1007/s00228-009-0717-5. Epub 2009 Aug 26. [PubMed:19707748 ]
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Vitamin d3 25-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiot...
Gene Name:
CYP3A4
Uniprot ID:
P08684
Molecular Weight:
57342.67 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Xenobiotic-transporting atpase activity
Specific Function:
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name:
ABCB1
Uniprot ID:
P08183
Molecular Weight:
141477.255 Da
References
  1. Ito T, Yano I, Tanaka K, Inui KI: Transport of quinolone antibacterial drugs by human P-glycoprotein expressed in a kidney epithelial cell line, LLC-PK1. J Pharmacol Exp Ther. 1997 Aug;282(2):955-60. [PubMed:9262363 ]
  2. Yamaguchi H, Yano I, Hashimoto Y, Inui KI: Secretory mechanisms of grepafloxacin and levofloxacin in the human intestinal cell line caco-2. J Pharmacol Exp Ther. 2000 Oct;295(1):360-6. [PubMed:10992002 ]
  3. Yamaguchi H, Yano I, Saito H, Inui K: Effect of cisplatin-induced acute renal failure on bioavailability and intestinal secretion of quinolone antibacterial drugs in rats. Pharm Res. 2004 Feb;21(2):330-8. [PubMed:15032316 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Sodium-independent organic anion transmembrane transporter activity
Specific Function:
Involved in the renal elimination of endogenous and exogenous organic anions. Functions as organic anion exchanger when the uptake of one molecule of organic anion is coupled with an efflux of one molecule of endogenous dicarboxylic acid (glutarate, ketoglutarate, etc). Mediates the sodium-independent uptake of 2,3-dimercapto-1-propanesulfonic acid (DMPS) (By similarity). Mediates the sodium-in...
Gene Name:
SLC22A6
Uniprot ID:
Q4U2R8
Molecular Weight:
61815.78 Da
References
  1. Uwai Y, Okuda M, Takami K, Hashimoto Y, Inui K: Functional characterization of the rat multispecific organic anion transporter OAT1 mediating basolateral uptake of anionic drugs in the kidney. FEBS Lett. 1998 Nov 6;438(3):321-4. [PubMed:9827570 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Quaternary ammonium group transmembrane transporter activity
Specific Function:
Mediates tubular uptake of organic compounds from circulation. Mediates the influx of agmatine, dopamine, noradrenaline (norepinephrine), serotonin, choline, famotidine, ranitidine, histamin, creatinine, amantadine, memantine, acriflavine, 4-[4-(dimethylamino)-styryl]-N-methylpyridinium ASP, amiloride, metformin, N-1-methylnicotinamide (NMN), tetraethylammonium (TEA), 1-methyl-4-phenylpyridiniu...
Gene Name:
SLC22A2
Uniprot ID:
O15244
Molecular Weight:
62579.99 Da
References
  1. Urakami Y, Akazawa M, Saito H, Okuda M, Inui K: cDNA cloning, functional characterization, and tissue distribution of an alternatively spliced variant of organic cation transporter hOCT2 predominantly expressed in the human kidney. J Am Soc Nephrol. 2002 Jul;13(7):1703-10. [PubMed:12089365 ]
  2. Okuda M, Urakami Y, Saito H, Inui K: Molecular mechanisms of organic cation transport in OCT2-expressing Xenopus oocytes. Biochim Biophys Acta. 1999 Mar 4;1417(2):224-31. [PubMed:10082798 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Symporter activity
Specific Function:
Sodium-ion dependent, low affinity carnitine transporter. Probably transports one sodium ion with one molecule of carnitine. Also transports organic cations such as tetraethylammonium (TEA) without the involvement of sodium. Relative uptake activity ratio of carnitine to TEA is 1.78. A key substrate of this transporter seems to be ergothioneine (ET).
Gene Name:
SLC22A4
Uniprot ID:
Q9H015
Molecular Weight:
62154.48 Da
References
  1. Yabuuchi H, Tamai I, Nezu J, Sakamoto K, Oku A, Shimane M, Sai Y, Tsuji A: Novel membrane transporter OCTN1 mediates multispecific, bidirectional, and pH-dependent transport of organic cations. J Pharmacol Exp Ther. 1999 May;289(2):768-73. [PubMed:10215651 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on December 08, 2016 03:55